

- I. AN INVESTIGATION OF CHYMOTRYPSIN A₁ INHIBITION
WITH PEPTIDE ALDEHYDES AND RELATED ANALOGS
- II. INHIBITION OF ELASTASE BY TETRAPEPTIDE
CHLOROMETHYL KETONES

A THESIS

Presented to

the Faculty of the Division of
Graduate Studies and Research

by

Ronald Jay Whitley


In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy in the
School of Chemistry

Georgia Institute of Technology


September, 1975

- I. AN INVESTIGATION OF CHYMOTRYPSIN A₁ INHIBITION
WITH PEPTIDE ALDEHYDES AND RELATED ANALOGS
- II. INHIBITION OF ELASTASE BY TETRAPEPTIDE
CHLOROMETHYL KETONES


Approved:



James C. Powers, Chairman



J. Aaron Bertrand



Erling Grovenstein, Jr.

Herbert O. House

Date approved by Chairman: Oct 3, 1975

ACKNOWLEDGMENTS

I would wish to offer sincere thanks to my research director, Dr. J. C. Powers, for expressing immeasurable amounts of advice and encouragement during my academic pilgrimage. I have been fortunate indeed to have had the opportunity to associate with this wise and patient biochemist. I would also thank Dr. Aaron Bertrand for many helpful discussions relevant to our X-ray crystallography efforts. In addition, I am grateful to Drs. Grovenstein, House and Bertrand for reading the manuscript and providing useful suggestions and comments. To my family, I would express deepest appreciation for always giving of their love and encouragement especially when it was most needed. To them, I dedicate this dissertation. I also want to acknowledge my backpacking partner, Peter Tuhy, and the many other students, faculty and friends who have helped to fill my student life with pleasant experiences. Finally, I want to thank Dr. Russell Dilday and the fellowship at Second-Ponce de Leon Baptist Church for their friendship as well as their Christian support during recent months of spiritual development and growth.

In connection with the experimental work, I wish to thank Mr. Rand Childs of Tech's Computing Services for his generous help and Dr. Aaron Janoff at the State University of New York at Stony Brook for the human leukocyte elastase used in inhibition studies.

TABLE OF CONTENTS

	Page
ACKNOWLEDGMENTS	ii
LIST OF TABLES	v
LIST OF ILLUSTRATIONS	vi
SUMMARY	viii

PART I

AN INVESTIGATION OF CHYMOTRYPSIN A_γ INHIBITION
WITH PEPTIDE ALDEHYDES AND RELATED ANALOGS

Chapter

I. INTRODUCTION	2
II. EXPERIMENTAL	9
III. RESULTS AND DISCUSSION	32
Synthesis of the Inhibitors Kinetics of Inhibition Effectiveness of Chymotrypsin Inhibitors Transition State Analogs of Chymotrypsin Effectiveness of Inhibitors with Subtilisin Ultraviolet Absorption Studies X-Ray Analysis of Inhibited Chymotrypsin A_γ	
IV. CONCLUSIONS	55
V. RECOMMENDATIONS	57
LITERATURE CITED	59

PART II

INHIBITION OF ELASTASE BY
TETRAPEPTIDE CHLOROMETHYL KETONES

Chapter

I. INTRODUCTION	64
Background Rationale for Development of Elastase Inhibitors	

TABLE OF CONTENTS (Continued)

Chapter	Page
II. EXPERIMENTAL	73
III. RESULTS AND DISCUSSION	80
Synthesis of the Inhibitors	
Kinetics of Inhibition	
Elastase Inhibition Studies	
Effectiveness of Porcine Pancreatic Elastase	
Inhibitors	
Effectiveness of Human Leukocyte Elastase	
Inhibitors	
Inhibition Studies with Trypsin and Chymotrypsin	
Significance of Results	
IV. CONCLUSIONS	97
V. RECOMMENDATIONS	98
LITERATURE CITED	99
VITA	102

LIST OF TABLES

PART I

AN INVESTIGATION OF CHYMOTRYPSIN A_γ INHIBITION
WITH PEPTIDE ALDEHYDES AND RELATED ANALOGS

Table	Page
1. Observed Dissociation Constants for Chymotrypsin A_γ Binding of Aldehydes, Alcohols and Semicarbazones	43
2. Unit Cell Dimensions of Native and Inhibited Crystals of Chymotrypsin A_γ (Space Group $P4_22_1$)	53

PART II

INHIBITION OF ELASTASE BY TETRAPEPTIDE
CHLOROMETHYL KETONES

Table	Page
1. Inhibition of Porcine Elastase with Tetrapeptide Chloromethyl Ketones	85
2. Inhibition of Human Leukocyte Elastase with Tetrapeptide Chloromethyl Ketones	86
3. Inhibition of Trypsin with Tetrapeptide Chloromethyl Ketones	93
4. Inhibition of α -Chymotrypsin with Tetrapeptide Chloromethyl Ketones	94
5. Inhibition of Chymotrypsin and Elastase with Tetrapeptide Chloromethyl Ketones	95

LIST OF ILLUSTRATIONS

PART I

AN INVESTIGATION OF CHYMOTRYPSIN A_γ INHIBITION
WITH PEPTIDE ALDEHYDES AND RELATED ANALOGS

Figure	Page
1. A Possible Mechanism of Action for Chymotrypsin	5
2. An Illustration of the Binding Interactions Between Trypsin and the Pancreatic Trypsin Inhibitor	7
3. Reaction Scheme for a Synthetic Preparation of Ac-Ala-Phe-H	38
4. Graphical Determination of the Dissociation Constant, K_I , for Ac-Ala-Phe-H by the Method of Dixon	42
5. Schematic Representation of Possible Binding Interactions Between Two Chromophoric Aldehydes and the Chymotrypsin Active Site	50
6. Scheme for Depicting the Positioning of a Polypeptide Substrate and an Imine of a Peptide Aldehyde in the Binding Site of a Protease	58

PART II

INHIBITION OF ELASTASE BY
TETRAPEPTIDE CHLOROMETHYL KETONES

Figure	Page
1. A Schematic Representation of Pancreatic Elastase Reactions with Substrates and Peptide Chloromethyl Ketone Inhibitors	68
2. Illustration Showing the Proposed Binding of Ac-Ala-Phe-CH ₂ Cl to Chymotrypsin A_γ	69
3. Diagram of Chymotrypsin A Showing the Extended Binding Site Region	70

LIST OF ILLUSTRATIONS (Continued)

Figure	Page
4. Final Synthetic Steps Used in the Preparation of Ac-Ala-Ala-Pro-Val-CH ₂ Cl	81
5. Structure of the Typical Peptide Chloromethyl Ketone Ac-Ala-Ala-Pro-Val-CH ₂ Cl	82

SUMMARY

PART I. AN INVESTIGATION OF CHYMOTRYPSIN A_γ INHIBITION
WITH PEPTIDE ALDEHYDES AND RELATED ANALOGS

Three peptide aldehydes and related analogs were synthesized and tested for their ability to generate models of the tetrahedral transition state for chymotrypsin-catalyzed substrate hydrolysis. Competitive inhibition experiments with chymotrypsin A_γ show that N-benzyloxycarbonylphenylalaninal (Z-Phe-H) was the most effective inhibitor, binding about 400-fold more tightly than comparable amide substrates. Two naphthalene aldehydes were also found to effectively inhibit A_γ , but significant spectral perturbations were not observed when either chromophoric aldehyde was complexed with the enzyme. X-ray crystallographic studies, however, suggest that Z-Phe-H and the dipeptide aldehyde Ac-Ala-Phe-H inhibit chymotrypsin A_γ crystals without altering unit cell dimensions. Semicarbazone derivatives of our peptide aldehydes were seen to be slightly less reactive than the corresponding aldehydes; peptide alcohols were unreactive. On the basis of these kinetic results, together with data from other investigators, we suggest that our aldehydes reversibly bind to chymotrypsin as covalent tetrahedral hemiacetals, and that these enzyme-aldehyde complexes are stereochemically analogous to the tetrahedral transition state for the hydrolysis reaction.

PART II. INHIBITION OF ELASTASE BY
TETRAPEPTIDE CHLOROMETHYL KETONES

Tetrapeptide chloromethyl ketones containing valine, isoleucine and threonine as the P_1 residues were synthesized as active-site directed irreversible inhibitors of elastase. Based on relative $k_{\text{obsd}}/[I]$ values, the P_1 -valine and isoleucine chloromethyl ketones were observed to be reactive and specific inhibitors for both porcine pancreatic elastase and human leukocyte elastase. The analogous threonine chloromethyl ketone was relatively unreactive. Trypsin and chymotrypsin which are closely related to elastase were not significantly inhibited by our tetrapeptide chloromethyl ketones. With porcine pancreatic elastase, the valine and isoleucine chloromethyl ketone inhibitors were as effective or slightly more effective than our standard P_1 -alanine tetrapeptide inhibitor. With human leukocyte elastase, on the other hand, the valine and isoleucine inhibitors were markedly more effective than the alanine ketone (the best one being Ac-Ala-Ala-Pro-Val-CH₂Cl). These results imply that the two elastolytic enzymes are different and distinct. Human leukocyte elastase is now implicated in the pathology of pulmonary emphysema and related inflammatory diseases. Eventually chloromethyl ketone inhibitors may become valuable in treating these diseases.

PART I

AN INVESTIGATION OF CHYMOTRYPSIN A_γ INHIBITION
WITH PEPTIDE ALDEHYDES AND RELATED ANALOGS

CHAPTER I

INTRODUCTION

Among those enzymes which catalyze hydrolysis reactions, proteases, or protein-cleaving enzymes, are certainly the most well-known and intensively studied. These enzymes provide a gentle, and in some cases, specific method of affecting hydrolysis of peptide bonds of polypeptide substrates. Moreover, proteolytic enzymes are efficient catalysts. They increase the hydrolysis rate by a factor of about 10^5 , thereby reducing the time taken for digestive processes involving these proteins from 50 years to a few hours.

Proteases are widely distributed in nature. In humans and other animals proteases are involved physiologically in such diverse biological functions as food digestion, blood coagulation, ovum fertilization and hormone production. In plants they catalyze the turnover of protein; in bacteria they presumably function as digestive enzymes. Because most of these proteases can be readily isolated and purified in large quantities, they are suitable for systematic study. Proteases for the most part are relatively simple, stable, low molecular weight enzymes, and the reactions they catalyze are generally not difficult to measure experimentally. Recently, they have attracted considerable attention in biomedicine due to their implication in certain diseases. Proteases are even becoming utilized commercially in the detergent and food processing industries.


Chymotrypsin (mw 25000) is a very well-characterized protease, and

most studies of this enzyme have been based on bovine pancreatic chymotrypsin A (EC 3.4.21.1). Originating in the acinous cells of the pancreas, chymotrypsin A is produced in the form of a catalytically inactive precursor called chymotrypsinogen. Activation of this zymogen is achieved by specific proteolytic hydrolysis of certain peptide bonds (Wilcox, 1970; Northrop et al., 1948). Biologically, active chymotrypsin serves as a catalyst in the hydrolysis of food proteins in the mammalian small intestine. Preferential cleavage of amide bonds occurs adjacent to the carboxyl function of aromatic amino acid residues such as L-Phe, L-Tyr and L-Trp (Cunningham, 1965; Nemeth and Schwert, 1950). Proteolysis also occurs adjacent to other large hydrophobic residues, as, for example, leucine and methionine, but usually at a slower rate (Brenner et al., 1960; Roveny et al., 1957). Although its natural substrates are polypeptides, chymotrypsin will hydrolyze specific substrates such as amides and esters of aromatic amino acids as well as a broad variety of other hydrophobic synthetic substrates and substrate analogs (Cunningham, 1965). As is the case with most enzymes, chymotrypsin activity varies with pH and is optimal between 7.5 and 9.0.

Four forms of chymotrypsin (α , γ , δ , π) result from proteolytic activation of chymotrypsinogen, but the α -form is the one that has been studied the most extensively. No structural differences have been found between the α and γ forms even though the two enzymes crystallize in different crystal habits and vary only slightly in their association behavior and reactivity in solution (Segal et al., 1971a). α -chymotrypsin contains 241 amino acid residues and 3 peptide chains (Meedom, 1959); its amino acid sequence has been determined by Hartley (1964) and Meloun et al.


(1966). X-ray crystallographic investigations have revealed the three-dimensional structures of tosyl-chymotrypsin and native chymotrypsin A at high resolution (Blow, et al., 1969; Blow, 1971; Birktoft and Blow, 1972). Further investigations have studied the three-dimensional structures of chymotrypsin A bound with a variety of substrates and inhibitors (Steitz et al., 1969; Henderson, 1970; Segal et al., 1971a,b). Based on crystallographic investigations of α -chymotrypsin, Blow and his coworkers (1969) have postulated a catalytic mechanism in which the linear arrangement of residues Ser-195, His-57 and Asp-102 functioned in such a way as to allow charge polarization at the active site. In this theory the electrons on the buried aspartate are relayed along hydrogen bonds to the serine hydroxyl group helping to make it strongly nucleophilic and thus explaining its reactivity. Powerful support for this theory has recently been received from nmr studies in solution (Robillard and Shulman, 1972, 1974a,b).

A comprehensive mechanism for chymotrypsin action (eq. 1), whose various features have been extensively studied, is schematically depicted in Figure 1. ES_1 is the noncovalent



Michaelis complex, and ES_{Tet} is a tetrahedral intermediate which precedes formation of the covalent acyl-enzyme, ES' . P_1 represents the initially released amine of an amide substrate, and ES'_{Tet} is a second tetrahedral intermediate preceding the regeneration of free enzyme and P_2 , the

Acylation



Deacylation




Figure 1. A Possible Mechanism of Action for Chymotrypsin. Note: From Zeffren and Hall, 1973.

carboxylic acid moiety. The inclusion of the two tetrahedral intermediates in this catalytic mechanism has been justified on several grounds (Zeffren and Hall, 1973; Hess, 1971; Jencks, 1969). Direct kinetic evidence for tetrahedral intermediate formation, however, has been supplied by Hess *et al.*, (1970). By employing temperature jump and stopped-flow kinetic techniques, the direct observation of two distinct chymotrypsin-substrate complexes prior to the formation of the acyl enzyme and release of P_1 were made possible. These intermediates were thought to be the Michaelis complex and a tetrahedral complex. Recently, crystallographic observations of tetrahedral adducts have been made in the bovine trypsin-basic pancreatic trypsin inhibitor complex (Ruhlman *et al.*, 1973), in the porcine trypsin-soybean trypsin inhibitor complex (Sweet *et al.*, 1974), and between aromatic boronic acids and subtilisin (Matthews *et al.*, 1975). In the case where the homologous chymotrypsin protease, trypsin, was complexed with the large pancreatic trypsin inhibitor (Figure 2), the O_Y atom of trypsin's Ser-195 was found to be covalently linked to the carbonyl carbon of Lys-15 of the inhibitor. The negatively charged oxygen at the tetrahedral carbon, moreover, was hydrogen bonded to the amide nitrogens of Gly-193 and Ser-195 of trypsin.

A great deal of information about binding specificity has been obtained from crystallographic investigations of chymotrypsin complexed with small molecules. For example, calculated electron density maps showed quite clearly that chymotrypsin's primary specificity site was a hydrophobic depression or pocket about $12 \times 6.5 \times 4 \text{ \AA}$ in size on the enzyme surface and into which the aromatic side chain of substrates or




Figure 2. An Illustration of the Binding Interactions Between Trypsin and the Pancreatic Trypsin Inhibitor.
Note: From Lilljas and Rossmann, 1974.

inhibitors could fit snugly (Steitz et al., 1969). Even though these and other binding interactions have been studied, little detailed information has been revealed concerning the structural and conformational changes that take place during chymotrypsin catalysis. This situation provides the incentive for the development of a structural model of the enzyme-substrate complex preceding acyl enzyme formation. As previously implied, it is generally supposed that this complex may be a highly activated tetrahedral intermediate which resembles a transition state for the hydrolysis reaction.

This thesis, Part I, reports our approach toward studying this important tetrahedral enzyme-substrate complex. The substrate analogs chosen for study are peptide aldehydes and related compounds. Their synthesis as well as their kinetics, ultraviolet, and crystallographic behavior are described. In addition, some explanations and implications of the data are considered.

CHAPTER II

EXPERIMENTAL

Materials and Methods

Chymotrypsin A (lot 53C-8130) and subtilisin BPN' (lot 102C-0650) were purchased from Sigma Chemical Co. and used without further purification in the kinetic studies; their substrate, N-acetyl-L-tyrosine ethyl ester (Ac-Tyr-OEt), was synthesized in our laboratory and had mp 80-81°. Chymotrypsinogen A (lot 111C-8170) and acetyl-tryptsin (lot 90C-2200) were also obtained from Sigma Chemical Co. and used without further purification. Diaflo ultrafilters used in enzyme concentration were purchased from Amicon Corp. Carboxymethyl cellulose, CM-52 microgranular, was purchased from Whatman Biochemicals Ltd. Sephadex G-25 fine was obtained from Pharmacia Fine Chemicals.

N-Benzylloxycarbonyl-L-phenylalanine chloromethyl ketone (Z-Phe-CH₂Cl) was prepared from Z-PheCHN₂ by the method of Shaw (1967). AgF and N,N-carbonyldiimidazole were purchased from PCR. N-methylaniline was obtained from Eastman Organic Chemicals and redistilled before use (B.P. 39°/300μ). 2-naphthaldehyde was purchased from Aldrich Chemical Co., Inc.; 1-naphthaldehyde was obtained from Eastman Organic Chemicals. Optically active amino acids were obtained from commercial sources. All other reagents and solvents were analytical grade.

Mass spectra were taken on a Perkin-Elmer Hitachi RMU-7L instrument, and nuclear magnetic resonance (nmr) spectra were taken on Varian A-60 or

T-60 instruments. Enzyme inhibition kinetics were performed on a Radiometer automated pH-stat system (model TTT 11). Ultraviolet absorption studies were performed on a Beckman Model-25 spectrophotometer. X-ray precession photographs were taken on a Buerger Precession Camera (Model 3000) supplied by Supper Co. Integrated intensities were measured from diffraction photographs by means of an automated Syntex microdensitometer.

Dihydro-4-Benzyl-2H-1,3-Oxazine-2,5(3H)-Dione

N-benzyloxycarbonyl-L-phenylalanine diazoketone (1.5 gm, 4.6 mmol), prepared from Z-Phe-OH and diazomethane using a mixed anhydride method (Penke et al, 1970), was dissolved in anisole (50 ml) and then added to a 10% ethereal solution of liquid anhydrous HF (3.0 gm, 15 mmol) in a polyethylene bottle at 0°C. Stirring was continued at room temperature until the reaction was complete as indicated by thin-layer chromatography. Work-up of the mixture involved evaporation of the solvent in vacuo, extraction of the residue into ethyl acetate, washing with citric acid and NaHCO₃ solutions, drying over anhydrous magnesium sulfate and evaporation to a yellow oil. The residue was then dissolved in chloroform and chromatographed on Merck silica gel G 0.063 - 0.2 mm. The product was isolated after elution with 2% methanol in chloroform. Recrystallization from ethyl acetate-cyclohexane gave 0.48 gm (51%) of a white solid, mp 135-136°, R_f .28 (CHCl₃ - CH₃OH, 9:1).

The nmr spectrum (CDCl₃) showed peaks at δ 7.30 (5H, s, Ph), 5.81(1H, b, NH), 4.53(2H, d, PhCH₂O), 4.11(1H, m, NHCHCO), 3.05(2H, complex, CH(CH₂)Ph). The mass spectrum showed major peaks at m/e

205(M^+ , 45.8%), 161($M - CO_2^+$, 16.7%), 118($NH = C(CH_2OH)^+$, 83.7%) and 91($C_7H_7^+$, base peak).

Anal. Calcd for $C_{11}H_{11}NO_3$: C, 64.39; H, 5.36; N, 6.81.

Found: C, 64.49; H, 5.22; N, 6.61.

N-Benzoyloxycarbonyl-L-Phenylalanine Hydroxymethylketone (Z-Phe-CH₂OH)

N-Benzoyloxycarbonyl-L-phenylalanine iodomethylketone was prepared by iodination of Z-Phe-CH₂Cl with sodium iodide in acetone. To a solution of Z-Phe-CH₂I (5.0 gm, 11.8 mmol) in acetonitrile (100 ml) was added a solution of AgF (4 gm, 32 mmol) in water (5 ml). After stirring for 30 minutes at 50°, the mixture was filtered and extracted with ethyl acetate (2 x 50 ml). The organic extracts were dried over magnesium sulfate and concentrated in vacuo to an oil. A solution of this oil in chloroform was then chromatographed on silica gel (60 gm). The crystalline product was isolated after elution with methanol-chloroform (1:100). Recrystallization from ethyl acetate-cyclohexane gave 1.8 gm (48%) of a white solid, mp 88-89°, R_f .41 ($CHCl_3$ -CH₃OH, 1:24), $ir(CHCl_3)$, 1717 cm^{-1} (C=O). The nmr spectrum ($CDCl_3$) showed peaks at δ 7.36(10H, m, Ph), 7.05(1H, m, NH), 5.10(2H, s, PhCH₂O), 5.28(1H, b, CH₂OH), 4.60(1H, m, NHCHCO), 4.18(2H, s, CH₂OH), 3.06(2H, d, PhCH₂CH). The nmr spectrum (DMSO) showed the hydroxyl proton peak at 5.35(1H, t, CH₂OH, which disappeared upon adding D₂O). A singlet instead of a triplet appeared in the double resonance spectrum (DMSO) of this compound, indicating that the spin-spin coupling between the methylene and hydroxyl hydrogens had been destroyed when the methylene hydrogens were irradiated. The mass spectrum showed major peaks at m/e 313(M^+ , .16%),

282($\text{PhCH}_2\text{OCONHCH}(\text{CH}_2\text{Ph})\text{CO}^+$, 1.1%), 254($\text{PhCH}_2\text{OCONHCH}(\text{CH}_2\text{Ph})^+$, base peak), 210($\text{PhCH}_2\text{NH}=\text{CHCH}_2\text{Ph}^+$, 73.7%), 91(C_7H_7^+ , 78.9%).

Anal. Calcd for $\text{C}_{18}\text{H}_{19}\text{NO}_4$: C, 68.98; H, 6.11; N, 4.47.

Found: C, 68.87; H, 6.14; N, 4.42.

N-Benzylloxycarbonyl-L-Phenylalaninal (Z-Phe-H) was prepared using methods developed by Japanese workers (Saeki *et al.*, 1973; Shimizu *et al.*, 1972; Ito *et al.*, 1972). N-benzylloxycarbonyl-L-phenylalanine (4.5gm, 15 mmol) was dissolved in dry tetrahydrofuran and cooled to 10° in a three-necked flask equipped with drying tube, thermometer, rubber septum and magnetic stirrer. N,N-carboxyldiimidazole (2.7 gm, 16.8 mmol) was added and the resulting pale yellow solution stirred for 15 minutes. After cooling the reaction mixture to -15° in ethylene glycol/dry ice, .788 M lithium aluminum hydride in tetrahydrofuran (28.5 ml, 22.5mmol) was slowly added dropwise. Stirring was continued an additional 45 minutes at -15° . Excess LiAlH_4 was then destroyed by slowly adding dropwise 30 ml of ice cold 1 M NH_4Cl . The reaction mixture was filtered and the precipitates washed with boiling ethyl acetate (3 x 50 ml) to remove any occluded organic product. After evaporation of the tetrahydrofuran, the residue was suspended in ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous magnesium sulfate and evaporated to give a crude pale yellow oil.

This oil was dissolved in chloroform and chromatographed on Merck silica gel G 0.063 - 0.2 mm. The product which eluted with chloroform-methanol (65:1) was recrystallized from ethyl acetate-cyclohexane to give a white crystalline solid (1.3 gm, 30%), mp $78-79^\circ$,

R_f .73(CHCl_3 - CH_3OH , 19:1), $\text{ir}(\text{CHCl}_3)$, 1720 cm^{-1} ($\text{C}=\text{O}$). The nmr spectrum (CDCl_3) showed peaks at δ 9.75(1H, s, CHO), 7.47(10H, m, Ph), 5.17(2H, s, PhCH_2O), 4.52(1H, m, NHCHCO), 3.14(2H, d, CHCH_2Ph).

The mass spectrum showed major peaks at m/e 283(M^+ , .13%), 254($(\text{M}-\text{CHO})^+$, 22%), 210($\text{PhCH}_2\text{CHCHCH}_2\text{Ph}^+$, 14%), 164 ($\text{PhCH}_2\text{OCONHCH}_2^+$, 5.3%) 91(C_7H_7^+ , base peak).

Further elution with chloroform-methanol (24:1) gave a second crystalline product, N-benzyloxycarbonyl-L-phenylalaninol. Recrystallization from ethyl acetate-cyclohexane gave 0.8 gm(19%) of a white solid, mp 94-94.5°, R_f .51(CHCl_3 - CH_3OH , 19:1).

The nmr spectrum (CDCl_3) showed peaks at δ 7.30(10H, d, Ph), 5.18 1H, b, NH), 5.07(2H, s, PhCH_2O), 3.89(1H, m, NHCH), 3.61(2H, m, CHCH_2OH), 2.84(2H, d, CHCH_2Ph), 2.31(1H, s, CH_2OH , which disappeared upon adding D_2O).

The mass spectrum showed major peaks at m/e 285(M^+ , .15%), 254($(\text{M}-\text{CH}_2\text{OH})^+$, 1.4%), 210($\text{PhCH}_2\text{NHCHCH}_2\text{Ph}^+$, 1.4%), 194($(\text{M}-\text{C}_7\text{H}_7)^+$, 11.6%), 150($\text{PhCH}_2\text{CH}(\text{NH})\text{CH}_2\text{OH}^+$, 4.8%), 91(C_7H_7^+ , base peak).

Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{NO}_3$: C, 71.58; H, 6.67; N, 4.91.

Found: C, 71.60; H, 6.74; N, 4.89

N-Benzyloxycarbonyl-L-Phenylalaninal Semicarbazone

To the crude oil of N-benzyloxycarbonylphenylalaninal was immediately added a solution of semicarbazide hydrochloride (4.5 g) and sodium acetate (7.8 gm) in water (50 ml). The mixture was shaken vigorously, warmed on a steam bath for 15 minutes, treated with 95% ethanol until turbidity just disappeared, and then placed in the refrigerator

overnight. The reaction mixture was diluted with a small amount of water to separate an oil. The solvent was decanted and the residual oil dissolved in ethanol and filtered. The filtrate was cooled in an ice bath and water gradually added until turbidity. The mixture was allowed to stand for several days in the refrigerator. A crystalline product was isolated and recrystallized from ethyl acetate-cyclohexane-methanol to give 1.8 gm (43%) of a white solid, mp 130-131°.

R_f 0.74 (CHCl_3 - CH_3OH , 4:1).

The nmr spectrum (CDCl_3) showed peaks at δ 9.66(1H, s, $\text{CH}=\text{NNH}$), 7.36 (10H, d, Ph), 7.07(1H, d, CHCHNNH), 6.18(1H, b, CONHCH), 5.68(2H, b, CONH_2), 5.04(2H, s, PhCH_2O), 4.56(1H, m, NHCHCH_2Ph), 2.95(2H, d, CHCH_2Ph).

The mass spectrum showed major peaks at m/e 340 (M^+ , .6%), 282 ($\text{PhCH}_2\text{OCONHCH}(\text{CH}_2\text{Ph})\text{CH}=\text{NH}^+$, 4.8%), 189 ($\text{PhCH}_2\text{CHCNNHCONH}_2^+$, 11.4%), 150 ($\text{PhCH}_2\text{OCONH}^+$, 14%), 108 (PhCH_2OH^+ , 33%), 91 (C_7H_7^+ , base peak).

Anal. Calcd for $\text{C}_{18}\text{H}_{20}\text{N}_4\text{O}_3$: C, 63.53; H, 5.88; N, 16.47
Found: C, 63.58; H, 5.96; N, 16.42.

Formyl-L-Phenylalanine (CHO-Phe-OH)

Formyl-L-phenylalanine was prepared by the peptide coupling method of du Vigneaud et al. (1932). To a mixture of L-phenylalanine (49.5 gm, 0.30 mole) in refluxing 97% formic acid (160 ml) was added dropwise acetic anhydride (29.1 ml, 0.28 mmol). The reaction mixture was stirred for 5 minutes and then quenched with 90 ml of ice water. Evaporation of the mixture in vacuo gave a crystalline product which was recrystallized from hot water to give 51 gm (88%) of a white solid, mp 171-172°. Lit: mp 168° (Fisher and Schoeller, 1907).

Formyl-L-Phenylalaninal (CHO-Phe-H)

To a solution of formyl-L-phenylalanine (3.9 gm, 20 mmol) in anhydrous tetrahydrofuran (150 ml) was added N,N-carbonyldiimidazole (3.6 g, 22.2 mmol). The colorless solution was stirred at 15° for 10 minutes and then cooled to -15°. 1.15 M lithium aluminum hydride in tetrahydrofuran (26 ml, 30 mmol) was subsequently added dropwise over a 15 minute period; excess reagent was destroyed by addition of ice cold 1 M NH₄Cl (50 ml). After evaporation of the tetrahydrofuran under N₂, the residue was suspended in ethyl acetate. The precipitates were then quickly filtered and washed with solvent to remove occluded organic products. The ethyl acetate extracts were combined, dried over anhydrous magnesium sulfate, and evaporated to a colorless oil. This crude oil rapidly decomposes and yellows unless stored immediately under nitrogen in the freezer.

Isolation of pure aldehyde involved several purification steps. The crude oil was dissolved in chloroform and chromatographed on Merck silica gel G, 0.063-0.2 mm. Elution with chloroform-methanol (19:1) gave aldehyde-containing fractions which were then pooled and evaporated. Further separation of the aldehyde from traces of imidazole was effected by means of liquid chromatography using a 6' x 3/4" silica Woelm column and a chloroform-methanol solvent system (19:1). Aldehyde fractions were pooled, evaporated to a small volume (1 or 2 ml) and transferred to a Hickman still. After the complete removal of organic solvents, the pale yellow oil was distilled (160-190°, 400μ) to give a viscous, colorless oil which crystallized on cooling. Recrystallization from

ethyl acetate-cyclohexane gave a white solid (.4 gm, 12%), mp 65-70°, R_f .47 (CHCl_3 - CH_3OH , 9:1), ir (neat) 1728 cm^{-1} (C=O).

The nmr (CDCl_3) showed peaks at δ 9.56(1H, s, CHO), 8.23(1H, s, HCONH), 7.28(5H, s, Ph), 7.19(1H, b, CONH), 4.75(1H, q, NHCH), 3.14(2H, d, CH_2Ph).

The mass spectrum showed major peaks at m/e 177(M^+ , 2.9%), 159($(\text{M}-\text{H}_2\text{O})^+$, 7.0%), 148($(\text{M}-\text{CHO})^+$, 19.3%), 132($\text{PhCH}_2\text{CHCHO}^+$, 24.0%), 120($\text{PhCH}_2\text{CHNH}_2^+$, 32.1%), 91(C_7H_7^+ , base peak). The mass of the m/e 177 peak (M^+) was exactly measured at 177.0781 (177.0789 calculated for $\text{C}_{10}\text{H}_{11}\text{NO}_2$).

Formyl-L-Phenylalaninal Semicarbazone

To the crude oil of formylphenylalaninal was immediately added a solution of semicarbazide hydrochloride (4 gm) and sodium acetate (6 gm) in water (40 ml) and shaken vigorously. The mixture was treated with 95% ethanol until turbidity disappeared and then allowed to stand at 0-5° overnight. The semicarbazone derivative which separated from the solution was recrystallized from water, affording white needles (2.8 gm, 60%) mp 178-179°, R_f .46 (CHCl_3 - CH_3OH , 4:1).

The nmr (DMSO-d_6) showed peaks at δ 9.96(1H, s, NNH), 8.18(1H, d, CHCHNNH), 7.92(1H, s, HCO), 7.10(5H, s, Ph), 6.97(1H, b, CONHCH), 6.19(2H, s, CONH_2), 4.60(1H, m, NHCHCO), 2.80(2H, d, CH_2Ph)

The mass spectrum showed major peaks at m/e 234(M^+ , 5.3%), 189($(\text{M}-\text{HCONH}_2)^+$, 5.7%), 174 ($\text{PhCH}_2\text{CHCHNNHCO}^+$, 6.1%), 143($(\text{M}-\text{C}_7\text{H}_7)^+$, base peak), 100(HCONHCHCHNNH_2^+ , 77.2%), 91(C_7H_7^+ , 95.6%).

Anal. Calcd for $\text{C}_{11}\text{H}_{14}\text{N}_4\text{O}_2$: C, 56.41; H, 5.98; N, 23.93.

Found: C, 56.51; H, 6.12; N, 23.79.

N-Acetyl-L-Alanine (Ac-Ala-OH)

The acetylation of L-alanine was accomplished by adding dropwise acetic anhydride (40.0 ml, 0.47 m) to L-alanine (51.1 gm, 0.57m) in refluxing glacial acetic acid (300 ml). After stirring for an additional 20 minutes, the reaction mixture was cooled to room temperature by the addition of water (100 ml) and then evaporated to a yellow oil. The oil was washed with hot benzene (250 ml), the benzene was removed, and the resulting oil treated with ethyl acetate (375 ml). The product which crystallized immediately was isolated and recrystallized from hot ethyl acetate to yield a white solid (50.5 gm, 67%) mp 126-127°, $[\alpha]_D^{23} = -65.7^\circ$ (C3.8, H₂O); Birnbaum *et al.* (1952) report mp 125°, $[\alpha]_D^{25} = -66.2^\circ$ (C2.0, H₂O).

N-Benzylloxycarbonyl-L-Phenylalanine N-Methylanilide (Z-Phe-N(Me)Ph).

The N-methylanilide of N-benzylloxycarbonyl-L-phenylalanine was prepared from Z-Phe-OH and N-methylaniline using a mixed anhydride coupling method. One equivalent of isobutyl chloroformate (2.6 ml) was added to a solution of 1 equivalent of Z-Phe-OH (6.0 gm, 20 mmol) and 1 equivalent of N-methylmorpholine (2.2 ml) dissolved in anhydrous tetrahydrofuran at -15°. This mixture was stirred for approximately 10 minutes, 1 equivalent of N-methylaniline (2.1 ml) was added, and the mixture stirred for 1 hour as the solution was allowed to warm to room temperature. The hydrochloride salts were filtered, water was added, and then the tetrahydrofuran was evaporated. The water solution was extracted at least three times with ethyl acetate. The combined ethyl acetate extracts were washed with 0.5 M citric acid and 1.0 M NaHCO₃ and then dried over anhydrous magnesium sulfate. Evaporation

of the ethyl acetate resulted in a colorless oil. This oil was dissolved in chloroform and chromatographed on Merck silica gel G 0.063 - 0.2 mm. The product eluted with 2% methanol in chloroform to give a colorless oil (6.8 gm, 87%), R_F .65 (CHCl_3 - CH_3OH , 19:1).

The nmr spectrum (CDCl_3) showed peaks at δ 7.01 (15H, m, Ph), 6.56 (1H, b, NH), 5.01(2H, s, PhCH_2O), 4.60(1H, m, NHCH), 3.13(3H, s, NCH_3), 2.88(2H, b, CH_2Ph).

L-Phenylalanine N-Methylanilide Hydrobromide ($\text{HBr} \cdot \text{PheN}(\text{Me})\text{Ph}$).

Z-Phe-N(Me)Ph (4.0 gm, 10.3 mmol) was deblocked by dropwise addition of a saturated solution of HBr in acetic acid. The reaction mixture was stirred for approximately 30 minutes. This procedure was repeated again until visible reaction ceased. Anhydrous ether (200 ml) was then slowly added to precipitate a yellow-orange oil. After vigorously shaking the reaction vessel, the ether was decanted from the residual oil. The oil was then washed with several portions of ether. The product crystallized but was too hygroscopic to isolate. It was immediately dissolved in dimethylformamide (10 ml) and used in further coupling reactions.

Acetyl-L-Alanyl-L-Phenylalanine N-Methylanilide ($\text{Ac-Ala-Phe-N}(\text{Me})\text{Ph}$)

Acetyl-L-alanine (prepared by the acetylation of L-alanine with 1 equiv of acetic anhydride in hot glacial acetic acid) was activated using the mixed-anhydride procedure. Acetyl-L-alanine (1.62 gm, 12.2 mmol) was dissolved in anhydrous tetrahydrofuran and cooled to -15° . N-methylmorpholine (1 equiv.) was added followed by 1 equiv. of

isobutyl chloroformate (1.6 ml). Deblocked Z-Phe-N(Me)Ph (4 gm, 12.2 mm, in 10 ml DMF) was added followed by 1 equiv. N-methylmorpholine (1.35 ml). The reaction mixture was allowed to warm to room temperature and stirring was continued for 1 hour. The hydrochloride salts were then filtered, water was added, the organic solvent evaporated, and the aqueous solution extracted with ethyl acetate. After aqueous citric acid and bicarbonate washes, the solvent was evaporated and gave a colorless oil. Purification was effected by chromatography on 0.063-0.2 mm silica gel G by Merck. The product which eluted with 4% methanol in chloroform was recrystallized from ethyl acetate-cyclohexane giving white needles (2.1 gm, 47%), mp 143.5-144, R_f .52 (CHCl_3 -MeOH, 19:1).

The nmr spectrum (CDCl_3) showed peaks at δ 7.77(1H, d, NH), 7.08 (10H, m, Ph), 6.90(1H, b, NH), 4.73(2H, m, NHCHCO), 3.24(3H, s, NCH₃), 2.87(2H, m, CH₂Ph), 1.86(3H, s, CH₃CO), 1.34(3H, d, CH(CH₃)CO).

The mass spectrum showed major peaks at m/e 367(M^+ , 2.7%), 281 ($\text{PhN(Me)COCH(CH}_2\text{Ph)NHCO}^+$, 1.6%), 276($(M-C_7H_7)^+$, 1.0%), 261($(M-NMePh)^+$, 19.5%), 237(PhCHCHCON(Me)Ph^+ , 15.9%), 233($M-\text{CON(Me)Ph}$, 2.7%), 146(PhCHCH(NH)CO^+ , 20.0%), 120($\text{PhCH}_2\text{CHNH}_2^+$, base peak), 114($\text{CH}_3\text{CONCHCH(CH}_3\text{)CO}^+$, 10.5%), 107(Ph(Me)NH^+ , 68.4%), 91(C_7H_7^+ , 8.6%).

Anal. Calcd for $\text{C}_{21}\text{H}_{25}\text{N}_3\text{O}_3$: C, 68.67; H, 6.81; N, 11.44.

Found: C, 68.57; H, 6.77; N, 11.38.

N-Acetyl-L-Phenylalaninal (Ac-ala-Phe-H)

Acetyl-L-alanyl-L-phenylalaninal was prepared from the N-methylanilide derivative of N-acetylalanylphenylalanine. Ac-Ala-Phe-N(Me)Ph (4.0 gm, 10.8 mmol) was dissolved in anhydrous tetrahydrofuran and cooled

to -15° . 1.15 M lithium aluminum hydride in tetrahydrofuran (19 ml, 21.6mmol) was slowly added dropwise. Stirring was continued an additional 75 minutes at -15° . Excess LiAlH_4 was destroyed by slowly adding dropwise cold 1 M NH_4Cl (15 ml). The precipitates were then filtered, the tetrahydrofuran evaporated and the residue suspended in ethyl acetate. After extracting the occluded solids with boiling ethyl acetate, the organic fractions were combined, dried over anhydrous magnesium and evaporated to a crude pale yellow oil.

This oil was dissolved in chloroform and chromatographed on 100-200 mesh Florisil. Elution with 3% methanol in chloroform gave the desired product as a colorless glass (1.2 gm, 42%), R_f .41 (CHCl_3 - CH_3OH , 9:1), ir (CHCl_3) 1730 cm^{-1} ($\text{C}=\text{O}$).

The nmr spectrum (CDCl_3) showed peaks at δ 9.38(.5H, s, CHO), 7.10(5H, s, Ph), 6.63(2H, b, NH), 4.43(2H, m, NHCH), 3.33(.5H, s, $\text{CH}(\text{OH})_2$), 3.03(2H, d, CH_2Ph), 2.70(1H, b, $\text{CH}(\text{OH})_2$, which disappeared upon adding D_2O), 1.87(3H, s, CH_3CO), 1.27(3H, m, $\text{CH}(\text{CH}_3)\text{CO}$)

The mass spectrum showed major peaks at m/e 262(M^+ , 2.3%), 245($(\text{M}-\text{OH})^+$, 29.7%), 234($(\text{M}-\text{CO})^+$, 10.3%), 201($(245-\text{CH}_3\text{CO})^+$, 20.0%), 120($\text{PhCH}_2\text{CHNH}_2^+$, base peak), 114($\text{CH}_3\text{CONHCH}(\text{CH}_3)\text{CO}^+$, 36.0%), 91(C_7H_7^+ , 88.6%). The mass of the m/e 244 peak ($\text{M}-\text{H}_2\text{O}$) was exactly measured at 244.1224 (244.1212 calculated for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2$).

In addition to the desired aldehyde, two additional products from the Florisil chromatography were isolated and crystallized.

N^1 -(acetylalanyl)- N^2 -phenyl- N^2 -methyl-1-benzyl-1,2-ethylenediamine
 ($\text{Ac-Ala-NHCH}(\text{CH}_2\text{Ph})\text{CH}_2\text{N}(\text{Me})\text{Ph}$) was eluted with 2% methanol in chloroform and was recrystallized from ethyl acetate-cyclohexane to yield a white

solid (.5 gm, 13%), mp 181-181.5°, R_f .60 (CHCl_3 - CH_3OH , 19:1).

The nmr spectrum (CDCl_3) showed peaks at δ 7.00(10H, m, Ph), 6.36(1H, b, NH), 4.36(2H, m, NHCHCO), 3.45(2H, t, $\text{CHCH}_2\text{NMePh}$), 2.99(3H, s, NCH_3), 2.88(2H, d, CH_2Ph), 1.89(3H, s, CH_3CO), 1.13(3H, d, $\text{CH}(\text{CH}_3)\text{CO}$).

The mass spectrum showed major peaks at m/e 353(M^+ , 3.3%), 267($\text{PhN(Me)CH}_2\text{CH}(\text{CH}_2\text{Ph})\text{NHCO}^+$, .7%), 223($\text{PhCH}_2\text{CHCHN(Me)Ph}^+$, 14.0%), 208($\text{PhCH}_2\text{CHCHNPh}^+$, .6%), 132(PhN(Me)CCH_2^+ , 2.7%), 120(PhN(Me)CH_2^+ , base peak), 91(C_7H_7^+ , 5.9%).

Anal. Calcd for $\text{C}_{21}\text{H}_{27}\text{N}_3\text{O}_2$: C, 71.39 H, 7.65; N, 11.90.

Found: C, 71.41; H, 7.70; N, 11.88.

Further elution with chloroform-methanol (19:1) gave a second crystalline product, N-acetylalanylphenylalaninol ($\text{Ac-Ala-NHCH}(\text{CH}_2\text{Ph})\text{CH}_2\text{OH}$). Recrystallization from ethyl acetate-cyclohexane gave .8 gm, (28%) of a white solid, mp 136-138°, R_f .35 (CHCl_3 - CH_3OH , 19:1),

The nmr spectrum (CDCl_3) showed peaks at δ 7.28 (5H, s, Ph), 7.11(1H, b, NH), 6.62(1H, b, NH), 4.45(2H, m, NHCHCO), 3.64(2H, d, CH_2OH), 3.56(1H, b, OH , which disappeared upon adding D_2O), 2.92(2H, d, CH_2Ph), 1.98(3H, s, CH_3CO), 1.37(3 H, d, $\text{CH}(\text{CH}_3)\text{CO}$).

The mass spectrum showed major peaks at m/e 265(M^+ , 2.2%), 264(M^+ , 1.5%), 246($M-\text{H}_2\text{O}$, .38%), 234 ($(265-\text{CH}_2\text{OH})^+$, 9.8%), 173($(M-\text{C}_7\text{H}_7)^+$, 15.5%), 155($(M-\text{H}_2\text{O}-\text{C}_7\text{H}_7)^+$, 10.5%), 134($\text{PhCH}_2\text{CH}_2\text{CHO}^+$, 15.8%), 130($\text{CH}_3\text{CONHCH}(\text{CH}_3)\text{C(OH)=NH}_2^+$, 65.4%), 120($\text{PhCH}_2\text{CHNH}_2^+$, base peak), 114($\text{CH}_3\text{CONHCH}(\text{CH}_3)\text{CO}^+$, 82.0%), 91(C_7H_7^+ , 40.6%), 86($\text{CH}_3\text{CONHCH}(\text{CH}_3)^+$, 54.1%).

Anal. Calcd for $\text{C}_{14}\text{H}_{20}\text{N}_2\text{O}_3$: C, 63.64; H, 7.58; N, 10.60.

Found: C, 63.65; H, 7.63; N, 10.52.

N-Acetyl-L-Alanyl-L-Phenylalaninal Semicarbazone

N-acetylalanylphenylalaninal semicarbazone was prepared by adding a solution of semicarbazide hydrochloride (.9 gm) and sodium acetate (1.4 gm) in water (9 ml) to N-acetylalanylphenylalaninal (.9 gm). The reaction mixture was vigorously shaken, warmed on a steam bath for 10 minutes, diluted with 95% ethanol (9 ml), shaken again and finally allowed to stand at 0-5°. After several days, the reaction mixture was evaporated to an oil in vacuo, dissolved in 10% methanol in chloroform, and chromatographed on Merck silica gel 0.063 - 0.2 mm. The semicarbazone derivative was eluted with chloroform-methanol (3:1) and was recrystallized from methanol-acetone to give a white solid (.6 gm, 55%), mp 206-207°, R_f .48 (CHCl_3 - CH_3OH , 4:1), R_f .48(CHCl_3 - CH_3OH , 4:1).

The nmr spectrum (DMSO-d₆) showed peaks at δ 9.95(1H, s, NNH), 8.17(1H, b, CHCHNNH), 7.98(1H, b, CONHCH), 7.28(5H, s, ph), 7.20(1H, b, CONHCH), 6.32(2H, s, CONH_2), 4.50(2H, m, NHCHCO), 2.90(2H, d, PhCH_2), 1.87(3H, s, CH_3CO), 1.07(3H, d, $\text{CH}(\text{CH}_3)\text{CO}$).

The mass spectrum showed major peaks at m/e 319 (M^+ , .26%), 261($\text{CH}_3\text{CONHCH}(\text{CH}_3)\text{CONHCH}(\text{CH}_2\text{Ph})\text{C}=\text{NH}^+$, .88%), 234($\text{CH}_3\text{CONHCH}(\text{CH}_3)\text{CONHCH}_2(\text{CH}_2\text{Ph})^+$, 6.4%), 228($(\text{M}-\text{C}_7\text{H}_7)^+$, 10.8%), 185($\text{CH}_3\text{CONHCH}(\text{CH}_3)\text{CONHC}=\text{CH}-\text{N}=\text{NH}_2^+$, 6.5%), 148($\text{NH}_2\text{CH}(\text{CH}_2\text{Ph})\text{CO}^+$, 4.2%), 130($\text{CH}_3\text{CONHCH}(\text{CH}_3)\text{C}(\text{OH})=\text{NH}^+$, 18.3%), 120($\text{PhCH}_2\text{CHNH}_2^+$, 39.4%), 91(C_7H_7^+ , base peak).

Anal. Calcd for $\text{C}_{15}\text{H}_{21}\text{N}_5\text{O}_3$: C, 56.43; H, 6.58; N, 21.94.
Found: C, 56.33; H, 6.67; N, 21.87.

3-(Benzyloxycarbonylamino)-4-Phenyl-1,2-Butanediol

3-Benzyloxycarbonylamino-4-phenyl-1,2-butanediol was prepared by

the sodium borohydride reduction of N-benzyloxycarbonylphenylalanine hydroxymethylketone. To a stirred solution of Z-Phe-CH₂OH (50 mg) in isopropanol (6 ml) was added solid NaBH₄ (1.6 mg). 90 minutes later, water (6 ml) and sodium chloride (.5 gm) were added. The mixture was then extracted with chloroform (2 times), dried over anhydrous magnesium sulfate, and evaporated to give a white solid, mp 110-111°.

The nmr spectrum (CDCl₃) showed peaks at δ 7.24(10H, d, Ph), 5.03(2H, s, PhCH₂O), 3.85(1H, b, NHCH(CH₂Ph)), 3.55(3H, m, CH(OH)CH₂(OH)), 2.84(4H, b, CH(CH₂Ph); and two OH, which were exchanged upon adding D₂O).

The mass spectrum showed major peaks at m/e 315(M+, 13%), 284(PhCH₂OCONHCH(CH₂Ph)CH(OH)+, .27%), 254(PhCH₂OCONHCH(CH₂Ph)+, 1.7%), 224 ((M-C₇H₇)+, 6.4%), 210(PhCH₂NHCHCH₂Ph+, 3.0%), 164(PhCH₂NHCHCH₂Ph+, 3.4%), 116(CH₂(OH)CH(OH)CH=NCO+, 70.9%) 108(PhCH₂OH+, 43.6%), 91(C₇H₇+, base peak).

Oxidation of Diol

N-Benzyloxycarbonylphenylalaninal (Z-Phe-H) was prepared by the periodic acid oxidation of 3-benzyloxycarbonylamino-4-phenyl-1,2-butane-diol. The diol (.16mm) was dissolved in anhydrous tetrahydrofuran and then reacted with H₅I₆ (68 mg). After stirring 1 hour at room temperature, the reaction mixture was filtered to remove precipitated iodic acid. The tetrahydrofuran was evaporated and the residual oil extracted with ethyl acetate. The ethyl acetate solution was washed with water, 1 M bicarbonate, water, saturated KCl solution, dried over anhydrous magnesium sulfate, and evaporated to a colorless oil. The pure product was identical (nmr, TLC) with an authentic sample of Z-Phe-H.

β -(2-Naphthyl)acrolein(2-C₁₀H₇CH=CH-CHO) was prepared from 2-naphthaldehyde and acetaldehyde by a procedure similar to that reported by Israelashvili *et al.* (1951). Upon workup, the crude aldehyde was obtained as a black oil. Purification was effected by chromatography on 0.05 - 0.2 mm silica gel G. The product was eluted with 10% ethyl acetate in pentane and was crystallized from ethyl acetate-cyclohexane as yellow needles, mp 125-126° (Jutz (1958) reports mp 125°); R_f .18(ethyl acetate-cyclohexane, 1:19); γ_{\max} (CHCl₃), 1678 cm⁻¹(C = O); λ_{\max} (EtOH) 274(ε35000) and 313(ε30000).

The nmr spectrum showed peaks at δ 9.70(1H, d, CHO), 7.2-8.1(8H, complex, C₁₀H₇CH) and 6.72(1H, d of d, J = 8 Hz, CH=CH-CHO). The mass spectrum showed major peaks at m/e 182(M⁺, base peak), 165((M-OH)⁺, 7.5%), 153((M-CHO)⁺, 80.5%), 141((M-CHCHO)⁺, 18.2%), and 128((M-C=CHCHO)⁺, 66.7%).

β -(1-Naphthyl)acrolein(1-C₁₀H₇CH=CH-CHO) was prepared from 1-naphthaldehyde and acetaldehyde by a procedure similar to that reported by Israelashvili *et al.* (1951). Upon workup, the crude aldehyde was obtained as a yellow oil (B.P. 190°/400μ). Purification was effected by chromatography on 0.05-0.2 mm silica gel G. The product eluted with 5% ethylacetate in pentane and was crystallized from 5% ethyl acetate in cyclohexane as colorless needles, mp 48.5-49° (Jutz (1958) reports mp 47-48°); R_f .14(ethyl acetate-cyclohexane, 1:19); γ_{\max} (neat), 1677 cm⁻¹(C=O); λ_{\max} (EtOH) 254(ε21500) and 340(ε12500).

The nmr spectrum showed peaks at δ 9.73(1H, d, CHO), 7.2-8.3(8H, complex, C₁₀H₇CH), 6.67(1H, d of d, J = 8 Hz, CH=CH-CHO). The mass spectrum showed major peaks at m/e 182(M⁺, 71.4%) 165((M-OH)⁺, 10.8%), 153((M-CHO)⁺,

base peak), and 128((M-C=CHCHO)+, 25.8%).

N-Acetyl-L-Phenylalanine Methyl Ketone (Ac-Phe-CH₃)

The diazoketone Ac-Phe-CHN₂ was prepared from acetyl-L-phenylalanine and diazomethane using a mixed-anhydride procedure. Ac-Phe-OH (1.0 gm, 5 mmol) was dissolved in tetrahydrofuran and cooled to -10° in a three-necked flask equipped with stirrer, drying tube and thermometer. N-methylmorpholine (.55 ml, 5 mmol) was added, followed by isobutylchloroformate (.65 ml, 5 mmol); mixed anhydride formation was practically instantaneous. After ca 10 minutes, the N-methylmorpholine salts were filtered and diazomethane (10 mmol) added. The reaction mixture was allowed to stand overnight at 4°C. Excess 51% hydriodic acid was added at 5°C. Stirring was continued until nitrogen evolution diminished. After workup of the reaction mixture, the resulting crude oil was chromatographed on silica gel. The product was eluted with 3% methanol in chloroform and recrystallized from ethyl acetate-cyclohexane to give white needles, mp 120-120.5, R_f .47(chloroform-methanol, 9:1). The nmr spectrum (CDCl₃) showed peaks at δ 7.23(5H, s, Ph), 7.12(1H, b, NH), 4.85(1H, m, NHCHCO), 3.09(2H, d, PhCH₂CH), 2.13(3H, s, CHCOCH₃), 1.94(3H, s, CH₃CONH).

The mass spectrum showed major peaks at m/e 205(M⁺, 3%), 162(Ac-NHCH(CH₂ Ph)+, 50%), 120(NH₂CH(CH₂ Ph)+, base peak), 91(C₇H₇⁺, 28%), 43(CH₃CO+, 38%).

Anal. Calcd for C₁₂H₁₅NO₂: C, 70.24; H, 7.32; N, 6.83.
Found: C, 70.34; H, 7.40; N, 6.77.

Reaction of Chymotrypsin with Inhibitors

The competitive inhibition of chymotrypsin A_Y was carried out under pseudo-first-order conditions at $25.0^\circ \pm .5$ and pH $7.80 \pm .10$. Stock inhibitor solutions were prepared by dissolving a weighed amount of inhibitor in 1,2-dimethoxyethane (DME) which had been redistilled over CaH_2 and stored over 4\AA molecular sieves. Inhibitor solutions at appropriate concentrations were prepared by serial dilution of the stock solutions with DME. A stock solution of chymotrypsin, prepared in 1.0 mM HCl, was stored at 4° and had a concentration of 13mM or 3.1 mg/ml as determined by uv absorbance at 282 nm. N-acetyl-L-tyrosine ethyl ester (Ac-Tyr-OEt) solutions were prepared by serial dilution of a 5 mM Ac-Tyr-OEt solution containing 0.1 F CaCl_2 and 5% (v/v) DME. The inhibition reaction was begun by adding 100 μl of an inhibitor solution to 10.0 ml of an Ac-Tyr-OEt solution, adjusting the pH to 7.8, and then adding a 100 μl aliquot of an enzyme solution which had been prepared by diluting 0.2 ml of the stock chymotrypsin solution with distilled water. The final enzyme concentration was $0.023\text{ }\mu\text{M}$. The rate of hydrolysis of Ac-Tyr-OEt by chymotrypsin was measured potentiometrically using a pH-stat. All assays were carried out in a thermostated vessel under a nitrogen atmosphere. The titrant used was 0.0470 F NaOH (0.1085 F in some later runs). Three substrate concentrations (1.0, 2.0 and 3.0 mM Ac-Tyr-OEt) were used for each inhibitor concentration with each point being replicated at least two times. Initial velocities were obtained from the pH-stat recorder tracings by the method of Henderson (1971).

For each inhibitor a value of the dissociation constant, K_I , was

calculated from an Eadie-Hofstee form of the Michaelis-Menton equation (eq. 2)

$$\frac{v}{s} = \frac{V_{\max}}{(1 + \frac{I}{K_I})(K_m)} - \frac{v}{(1 + \frac{I}{K_I})(K_m)} \quad (2)$$

using a least-squares computer program. Correlation coefficients of better than 0.96 were obtained throughout.

Reaction of Subtilisin with Inhibitors

The competitive inhibition of subtilisin BPN' was carried out under conditions virtually identical with those employed in the inhibition reactions with chymotrypsin. Solutions of inhibitor and substrates were made up to the correct concentrations as previously described for chymotrypsin. A stock subtilisin solution was freshly prepared each day by dissolving 1.9 mg of enzyme in 1.0 ml of a 0.1 M phosphate buffer at pH 7.0. The enzyme concentration was determined by uv absorbance at 280 nm. The inhibition reaction was initiated by adding 100 μ l of an inhibitor solution to 10.0 ml of an Ac-Tyr-OEt solution, adjusting the pH to 7.8, and then adding a 250 μ l aliquot of an enzyme solution which had been prepared by diluting 0.5 ml of the stock subtilisin solution with distilled water. The inhibition kinetics were assayed and analyzed as previously described for chymotrypsin.

Preparation of Crystals of Chymotrypsin A_γ for X-ray Analysis.

Crystallization leading to a limited number of single crystals of uniform size was carried out as follows. Lyophilized chymotrypsin A_γ (120 mg) was dissolved in 1 mM HCl to a concentration of 60 mg/ml. The

concentrated enzyme solution (2 ml) was filtered through a 0.9 x 25 cm column of G-25 fine Sephadex which had been thoroughly prewashed with distilled water. An effluent fraction of 4.0 ml containing most of the protein (as indicated by trichloroacetic acid precipitation) was collected in a dust free container, and the pH adjusted to 5.6. Aliquots (2 ml) of the solution were mixed in small dust free crystal dishes with equal volumes of a salt solution, 4.0 M $(\text{NH}_4)_2\text{SO}_4$ -0.02 M cacodylate buffer (pH 5.6). Care was taken not to nucleate the solution during mixing. The final enzyme concentration was ca. 15 mg/ml.

The dishes were seeded by touching the liquid surface with a glass fiber that had been dipped into the mother liquor of a stock preparation of tetragonal A_γ crystals. Each dish was then sealed and stored at 20°. Well-formed tetragonal bipyramids (the characteristic crystalline habit of bovine γ -chymotrypsin), appeared within a week. When these crystals had reached the size of 0.3 - 0.5 mm in the longest dimension (about two months), they were used in the x-ray studies.

Preparation of Tetragonal A_γ Crystals from Chymotrypsinogen

Seed crystals of chymotrypsin A_γ were grown from enzyme freshly derived from zymogen by rapid activation (Wilcox, 1970). Chymotrypsinogen (1.1g) was treated with acetyl-trypsin (40 mg) at 5° and pH 7.5 for 1 hr. The mixture of enzyme species was then separated on CM-cellulose at 5° using a .075 - .225 M phosphate linear gradient (pH 6.2). The major fraction consisting of A_δ was collected, the pH adjusted to 4.0, and the protein concentrated in an Amicon Diaflo apparatus, using UM 20 membranes. During this stage of the preparation, the A_δ species was largely converted

to A_γ . The concentrated enzyme solution was then filtered through G-25 fine Sephadex. After adjusting the pH to 5.6, aliquots of the solution were mixed with equal volumes of the saturated ammonium sulfate-cacodylate buffer salt solution previously described. Each dish was then sealed and stored at 20°. Small seed crystals appeared several months later.

Preparation of Inhibited Crystals for X-Ray Analysis

Chymotrypsin A_γ crystals, grown from a half-saturated ammonium sulfate (pH 5.6) salt solution, were allowed to soak in 2.4 M phosphate (pH 5.6) for 1 day to remove $(\text{NH}_4)_2\text{SO}_4$. Reaction of the crystals with each of the two inhibitors, Ac-Ala-Phe-H and Z-Phe-H, was carried out by the following procedure. Some of the aldehyde was dissolved in acetonitrile. This solution was then mixed with the 2.4 M phosphate (pH 5.6) salt solution to give a 1-2% acetonitrile mixture; γ -crystals were seen to be soluble in salt solutions containing 3-4% acetonitrile. Some of the inhibitor precipitated from the mixture, indicating saturation. A slurry was maintained by frequent stirring and was exchanged slowly with the solution which bathed the enzyme crystals. The reaction was allowed to proceed at 20° with occasional mixing and additions of fresh inhibitor solution. After approximately 2 weeks soaking, the crystals were then used for x-ray analysis since the inhibited crystals began to significantly crack after 3-4 weeks soaking.

X-ray Data Collection

Inhibited γ -chymotrypsin crystals of suitable size, typically 0.5 mm x 0.3 mm, were carefully positioned in acid-washed capillary tubes made of Lindmann glass. The c-axis (longest dimension) was oriented

approximately parallel to the capillary axis. Excess liquid was removed using slivers of filter paper, but the base of a crystal was left in a slight puddle. After sealing, the capillary tube was glued to a standard size metal pin, and the pin was then mounted on a standard goniometer head.

Crystals were aligned and centered on a Buerger precession camera fitted with a Polaroid XR-7 film cassette. Intensity data was collected by the precession method using Illford Industrial G X-ray film. Precession photographs at 8 and 16 hrs were obtained for the h0l level of each derivative crystal using filtered CuK_α radiation ($\lambda = 1.53 \text{ \AA}$). The crystal-to-film distance was 100 mm, and the precession angle was $16^\circ 45'$. A screen of 10 mm radius and a spacing of 33.3 mm were also used. All zero-level photographs, taken at spindle settings found during alignment and centering, possessed mirror-mirror symmetry. Integrated intensities were measured from these precession films using an automated microdensitometer. Control photographs of uninhibited crystals were supplied by Mr. D. Carroll.

Ultraviolet Absorption Studies

Ultraviolet absorption spectra were measured with matched, two-compartment cuvetts (path length, 0.44 cm per compartment) and a Beckman Model 25 recording spectrophotometer. Aldehyde solutions were freshly prepared by dissolving weighed amounts of β -(2-naphthyl)acrolein and β -(1-naphthyl) acrolein in 1,2-dimethoxyethane (DME) and diluting with pH 7.8 buffer (.1 M phosphate) resulting in a 10% DME solution. A stock solution of chymotrypsin A_γ was prepared in 1 mM HCl and had a

concentration of 0.11 mM by uv absorbance. Spectra were recorded at ambient temperature from 410 nm to 230 nm with aldehyde (compartment 1) and enzyme (compartment 2) in the sample beam vs .1 M phosphate buffer, pH 7.8, in the reference beam. Within 5 minutes of mixing the aldehyde and enzyme solutions contained in the sample cuvette, spectra were again recorded over the same wavelength range. Before mixing, concentrations were as follows: 2-C₁₀H₇CH=CH-CHO, 30 or 60 μ M; 1-C₁₀H₇CH=CH-CHO, 125 or 250 μ M; γ -chymotrypsin, 3 or 110 μ M.

In separate experiments, difference spectra were measured with aldehyde (compartment 1) and chymotrypsin (compartment 2) in the sample beam vs aldehyde and chymotrypsin (compartment 1) and pH 7.8 phosphate buffer (compartment 2) in the reference beam. In order to minimize error, the same pipet was used to prepare the sample and reference mixtures. Chymotrypsin was added to the cuvetts within 15 minutes of recording the spectrum from a stock solution (0.11 mM). Final concentrations were: 2-C₁₀H₇CH=CH-CHO, 15 or 30 μ M; 1-C₁₀H₇CH=CH-CHO, 75 or 125 μ M; γ -chymotrypsin, 55 μ M. Control runs, in which buffer was substituted for the enzyme or the inhibitor, were also performed. All spectra were recorded from 450 nm to 240 nm at 0.1 absorbance units full scale.


CHAPTER III

RESULTS AND DISCUSSION


Efforts were directed toward the development and study of a structural model of the tetrahedral enzyme-substrate complex preceding acyl enzyme formation. Specific goals were: a) the synthesis of a small inhibitor molecule resembling a natural substrate that would complex with either chymotrypsin or subtilisin such that the enzyme active site serine had added to the carbonyl group of the inhibitor. This derivative would be analogous to the tetrahedral intermediate observed in the enzymatic hydrolysis of the peptide bond by serine proteases; b) a kinetic and crystallographic investigation of this derivative.

Synthesis of the Inhibitors

Peptide fluoromethyl ketones were initially chosen to serve as our substrate analogs. Because peptide fluoromethyl ketones are structurally similar to normal chymotrypsin substrates, they were considered to be ideal analogs.




normal substrate




peptide fluoromethyl ketone

For example, the fluorine atom was not expected to participate in

nucleophilic displacement reactions. Hence, fluoromethyl ketones would probably not react with the enzyme's active site histidine residue. The fluoromethyl ketone functional group (COCH_2F), moreover, is about the same size and shape as a normal peptide amide bond and, due to the electronegative fluorine atom, might be expected to have almost the same polarity as a peptide bond. Thus, a complex of a peptide fluoromethyl ketone with chymotrypsin might exist in a form in which the active site serine (Ser-195) had added across the carbonyl group. This non-productive adduct would be expected to be an analog of the tetrahedral intermediate found to intervene in chymotrypsin acylation and deacylation and as such, would be a good candidate for x-ray crystallography. Although many different synthetic schemes and chemical systems were tried, attempts to prepare these peptide fluoromethyl ketones were not successful. For example, the reaction of a peptide diazoketone with anhydrous HF did not yield the expected fluoroketone even though analogous methods had been used to prepare chloromethyl ketones (Shaw, 1967). Instead a cyclization reaction occurred (eq. 3). The products




of the reactions of peptide iodomethyl ketones with AgF, on the other hand, were found to be the corresponding alcohols (eq. 4)



and not the expected primary alkyl halides (Tannhauser *et al.*, 1956).


Failing to realize our goals with peptide fluoromethyl ketones, efforts were then directed toward developing aldehyde analogs of peptide substrates. Being about the same size and shape as a peptide bond, the aldehyde functional group was considered to be ideal. Moreover, aldehydes are known to be very susceptible to carbonyl addition reactions and are frequently unstable in aqueous or alcohol solution, forming hydrates or hemiacetals. Hence, the hemiacetal (I), which is probably formed when a serine protease interacts with an aldehyde analog, should resemble the highly activated tetrahedral intermediate suggested in normal substrate hydrolysis of peptide bonds. Recent studies




have shown that aldehyde analogs of specific substrates are potent competitive inhibitors of trypsin, chymotrypsin, elastase and papain, binding many times more tightly than substrates. For example, two peptide aldehydes analogous to amide substrates of elastase have been synthesized by Thompson (1973) and shown to bind to the enzyme up to

5000-fold more tightly than the substrates. Aldehydes, structurally related to the acyl portion of papain substrates, have also been synthesized and found to be extremely potent competitive inhibitors (Westerik and Wolfenden, 1972). Interestingly, a novel class of naturally occurring peptide aldehydes, leupeptins, have been shown to effectively inhibit various proteases such as trypsin and papain (Aoyagi *et al.*, 1969a,b; Maeda, 1971), and their structures have been confirmed by synthesis (Shimizu *et al.*, 1972; Kawamura *et al.*, 1969, Kondo *et al.*, 1969). Furthermore, various synthetic analogs of these leupeptins have demonstrated marked inhibition of chymotrypsin (Ito, *et al.*, 1972).

The synthesis of peptides containing aldehyde functional groups represents a rather new experimental endeavor in synthetic peptide chemistry. Guided by the studies of several Japanese workers (Ito, *et al.*, 1972; Saeki *et al.*, 1973, Shimizu *et al.*, 1972), the synthesis of three P_1 -phenylalanine peptide aldehydes was undertaken. The dipeptide aldehyde, Ac-Ala-Phe-H (II), was to be prepared from Z-Phe-H (III) for use in




crystallography studies with chymotrypsin A_γ . CHO-Phe-H (IV), on the other hand, was designed for use with α -chymotrypsin since this enzyme crystal lattice was not expected to accommodate larger peptides (Birktoft *et al.*, 1970). Two of these inhibitors, CHO-Phe-H and Z-Phe-H were successfully synthesized by reducing the imidazolides of CHO-Phe-OH and Z-Phe-OH with LiAlH_4 in anhydrous tetrahydrofuran (eq. 5). Reduction of carboxylic acid



imidazolides with LiAlH_4 was originally reported by Staab and Braunling (1962) but first applied to peptide imidazole derivatives by Shimizu and coworkers in 1972. Little racemization was reported to have occurred during these reductions.

Crystalline Z-Phe-H was obtained readily after chromatographic purification. Conversion of the aldehyde to the corresponding semicarbazone confirmed our synthesis. An alternative synthesis of Z-Phe-H was effected by sodium borohydride reduction of the hydroxymethyl ketone, Z-Phe- CH_2OH , followed by periodic acid oxidation of the resulting 1,2-diol (eq. 6, $\text{R} = \text{Z-NH-CH}(\text{CH}_2\text{C}_6\text{H}_5)\text{-}$).



Purification of formylphenylalaninal (CHO-Phe-H) presented formidable difficulties. This compound was eventually obtained as a colorless oil by high pressure liquid chromatography. Distillation of this oil provided an air-sensitive, but crystalline, white solid. The aldehyde thus obtained was characterized as a crystalline semicarbazone.

Several approaches were considered in our attempts to prepare the N-acylated dipeptide aldehyde, Ac-Ala-Phe-H. Because the aldehyde functional group has a tendency to react with amino groups, the desired

compound must either be synthesized after the rest of the peptide has been constructed or should be protected (e.g. by means of a semicarbazone) during coupling reactions. The former approach was adopted after failing to remove the semicarbazone blocking group. Direct reduction of the corresponding imidazole derivative of Ac-Ala-Phe-OH was unsatisfactory because of the poor solubility of the starting amino acid in anhydrous tetrahydrofuran or diethyl ether. The synthesis of aldehydes by LiAlH_4 reduction of amides derived from N-methylaniline has been reported to give good results (Weygand et al., 1954). Consequently, synthetic efforts were directed toward the preparation of Ac-Ala-Phe-N(Me)Ph. Attempts to couple the dipeptide acid, Ac-Ala-Phe-OH, with N-methylaniline using the dehydrating agent dicyclohexyl carbodiimide (DCCI) resulted in the isolation of a racemized amide product. Varying amounts of racemization are often observed in DCCI coupling reactions, and, in those cases where certain N-acylated peptides are involved, can be identified by the nmr method of Weinstein and Prichard (1972). To circumvent this problem, a mixed-anhydride procedure was employed to prepare the optically active amide. The required sequence of reactions is shown in Figure 3.

N-acetyl-L-alanyl-L-phenylalaninal was obtained as a colorless glass after reducing the N-methylanilide with LiAlH_4 . The corresponding peptide alcohol and amine were also isolated from the reaction mixture. A crystalline semicarbazone derivative of the aldehyde was synthesized and characterized.

Although peptide aldehydes were specifically designed for use in crystallographic studies with chymotrypsin A, it seemed reasonable to suppose that aldehydes in general might be used to provide information





Figure 3. Reaction Scheme for a Synthetic Preparation of Ac-Ala-Phe-H.


about the structure of the enzyme complex in solution. Consequently, we prepared two intensely chromophoric aldehyde inhibitors,



V and VI, by slight modifications of published procedures (Israelashvili *et al.*, 1951). Both naphthalene aldehydes were crystallized and characterized for further use.

Kinetics of Inhibition

The most appropriate parameter used to compare the relative binding strengths of the various competitive inhibitors is the dissociation constant, K_I . For competitive inhibition (eq. 7) the rate of reaction of an




enzyme and its substrate in the presence of an inhibitor is described by eq. 8 where K_I is the

$$v = \frac{V_{\max} S}{K_m \left(1 + \frac{I}{K_I}\right) + S}
 \quad (8)$$

dissociation constant of the enzyme-inhibitor complex (eq. 9), K_m is the Michaelis constant and V_{\max} is the maximum initial velocity.

$$K_I = \frac{[E][I]}{[E \cdot I]} \quad (9)$$

In this study the chymotrypsin or subtilisin catalyzed hydrolysis of Ac-Tyr-OEt is followed both in the absence and presence of inhibitors by means of an automatic pH-stat titrator, which adds base to titrate the acid formed as a product in order to maintain the pH constant at 7.8 (eq. 10).




A strip chart recording was made of the volume of standard base added as a function of time, and this of course gave a direct measure of the rate of the reaction in question (Wilcox, 1970). These rates were then used to construct Eadie-Hofstee (v/s vs v) plots where v is the initial velocity of the Ac-Tyr-OEt hydrolysis and s is the substrate concentration. Of the various transformations of the Michaelis-Menten equation, this transformation has been shown to give more reliable results than the standard Lineweaver-Burke plot (Dowd and Riggs, 1965). The inhibition constants, K_I , were determined by calculation from the y-intercepts of these plots according to the relationship given in eq. 11. For comparison purposes, accurate dissociation

$$[\text{y-intercept}]_I = [\text{y-intercept}]_{\text{no } I} \left[\frac{1}{1 + \frac{[I]}{K_I}} \right] \quad (11)$$

constants were also conveniently calculated from Dixon ($1/v$ vs I) plots (Dixon, 1953) and found to give the same results. Typical data is shown in Figure 4. Table I presents the observed dissociation constants for chymotrypsin A_Y binding of several aldehydes, alcohols and semicarbazones.


Effectiveness of Chymotrypsin Inhibitors

The experimental results indicate that our strategy was generally successful for designing aldehydes which would be excellent competitive inhibitors at pH 7.8 and 25.0°. The best inhibitor was the peptide aldehyde N-benzyloxycarbonyl-L-phenylalaninal (Z-Phe-H, III). Its observed dissociation constant, 7.8×10^{-5} M, is indicative of a very strong enzyme-aldehyde complex, binding ca. 400-fold more tightly than the specific amide substrate Ac-Phe-NH₂ (VII) and CHO-Phe-NH(Et) (VIII). The magnitude of this dissociation



VII

$K_S = 31$ mM (Himoe et al., 1967)



VIII

$K_S = 20$ mM (Fersht and Requena, 1971)

constant compares favorably with that found by Ito et al. (1972) for Ac-Leu-Leu-Phe-H ($K_I = 5.2 \times 10^{-5}$ M).

The dipeptide aldehyde, Ac-Ala-Phe-H (II), was found to inhibit chymotrypsin with a K_I value of 6.7×10^{-4} M. In contrast, a structurally similar inhibitor, Ac-Ala-NHCH₂CH₂C₆H₅ ($K_I = 8.8$ mM) (Powers et al., 1974), lacking the reactive aldehyde functional group, was observed to bind 13 less effectively than II. Our dipeptide aldehyde, however, were not




Figure 4. Graphical Determination of the Dissociation Constant, K_I , for Ac-Ala-Phe-H by the Method of Dixon.
 Note: ATEE is the substrate, acetyltyrosine ethyl ester.

Table 1. Observed Dissociation Constants for Chymotrypsin A_γ -Binding of Aldehydes, Alcohols and Semicarbazones.^a

Inhibitor	K_I , mM (Std. deviation)	[I] range, mM
Z-Phe-H	0.078 (.003)	.03 - .05
semicarbazone	0.68 (.02)	.125 - .50
Z-phenylalaninol	> 5	.10 - .50
Ac-Ala-Phe-H	0.67 (.03)	.25 - 1.0
semicarbazone	4.5 (0.3)	1.0 - 3.5
Ac-Ala-Phenylalaninol	> 10	.10 - 1.0
CHO-Phe-H	<u>ca.</u> 8	1.0 - 5.0
semicarbazone	> 50	1.0 - 5.0
2-C ₁₀ H ₇ CH=CH-CHO	0.20 (.06)	.05 - .075
1-C ₁₀ H ₇ CH=CH-CHO	0.56 (.08)	.10 - .25
C ₆ H ₅ CH ₂ CH ₂ CHO	0.38 (.04)	.25 - 1.0
C ₆ H ₅ CHO	2.65 (.11)	.5 - 2.0
None	1.95 (.16) ^{b,c}	

^a) 5% (v/v) 1,2-dimethoxyethane, 0.10 \underline{F} CaCl₂, pH 7.80, 25.0°

^b) K_m for the hydrolysis of N-Acetyl-L-Tyrosine Ethyl Ester (Ac-Tyr-OEt)


^c) $V_{max} = 371 \pm 26$ μ moles substrate hydrolyzed/min/mg of enzyme.

as effective as the papain and elastase specific substrate aldehyde analogs which had binding constants of $10^{-7} \sim 10^{-8}$ M.

Formyl-L-phenylalaninal (IV) was observed to bind relatively poorly to γ -chymotrypsin. Surprisingly, the K_I value found for the binding of CHO-Phe-H at pH 7.8 is only 2-4 times better than the binding constants found for the amides VII or VIII. On the other hand, our data indicate that both chromophoric aldehydes, V and VI, were effective, competitive inhibitors of chymotrypsin, binding 50 to 150 times more tightly than VII.


Table I also includes apparent binding constants for a number of compounds related to our peptide aldehydes. These compounds, which include peptide semicarbazones and alcohols, were generally observed to be less tightly bound than the corresponding aldehydes. For example, the semicarbazone derivatives of Z-Phe-H and Ac-Ala-Phe-H were found to inhibit chymotrypsin approximately 7 to 9 times less effectively than their aldehyde counterparts. The analogous peptide alcohols, on the other hand, were not observed to inhibit chymotrypsin within the concentration limits of our experiments.

Two additional aldehydes were reacted with chymotrypsin. Hydrocinnaldehyde (IX), whose



IX

$$K_I = 3.8 \times 10^{-4} \text{ M}$$



X


$$K_I = 2.7 \times 10^{-3} \text{ M}$$

structure resembles hydrocinnamate ester and amide substrates, was


observed to effectively inhibit chymotrypsin at pH 7.8 and 250°. This behavior is consistent with previous binding studies of this aldehyde with chymotrypsin (Rawn and Lienhard, 1974; Schultz and Cheerva, 1975). In contrast, benzaldehyde (X), lacking the ethylene bridge contained in hydrocinnamaldehyde, was a poorer chymotrypsin inhibitor, suggesting to us that X, although capable of binding in the enzyme's hydrophobic specificity pocket, may not react with the nucleophilic serine hydroxyl group. Hydrocinnamaldehyde, on the other hand, is 7 times more tightly bound to the enzyme. This observation is consistent with the additional formation of a reversible covalent bond between hydrocinnamaldehyde and Ser-195.

It is informative at this point to question whether the free aldehydes or their hydrates are the inhibitory species. Several rapidly equilibrating enzyme-inhibitor complexes might conceivably account for the strong binding of our aldehydes. For example, it is possible that a stable noncovalent complex between the enzyme and the free aldehyde could occur. This situation, however, is considered unlikely. Since the aldehyde functional group is about the same size and shape as a peptide bond, it is expected that the carbonyl group of an aldehyde should bind closely to the strongly nucleophilic hydroxyl group of Ser-195. Because aldehydes are quite susceptible to carbonyl addition reactions, this conjunction would be an unstable situation leading rapidly to hemiacetal formation. On the other hand, a noncovalent complex of chymotrypsin with an aldehyde hydrate is certainly conceivable. Such a complex would avoid placing a reactive carbonyl group

in the enzyme's active site. However, N-benzyloxycarbonylphenylalaninol (XI) and N-acetyl-L-alanyl-L-phenylalaninol (XII), which might be considered reasonable analogs of the



(XI)



(XII)

hydrated aldehydes, are extremely poor inhibitors. Furthermore, if noncovalent binding of an aldehyde hydrate to chymotrypsin is indeed the structure of the complex, it is difficult to see why aldehyde hydrates, which are gem-diols, should bind so much better than the analogous alcohols. Hydrogen bonds between the enzyme and a second hydroxyl group, should they exist, would not be likely to greatly favor the binding of a diol over the corresponding alcohol. Therefore, it is probable that the free aldehyde (rather than the gem-diol) is the inhibitory species, and the covalent tetrahedral hemiacetal (I) best represents the structure of the aldehyde-enzyme complex.

To the extent that aldehyde hydrates are present in solution in equilibrium with the free aldehydes, apparent K_I values for the aldehydes in Table I are presumably higher than the true values. Thompson (1973) has shown that


$$K_I(\text{obsd}) = K_I(1 + K_{\text{Hy}})$$

where K_{Hy} is the formation constant for an aldehyde hydrate. Since to a first approximation K_{Hy} will be independent of remote structural


features of an aldehyde, this formation constant may equal that found for the hydration of acetaldehyde in water, i.e., $K_{Hy} = 1.4$ (Bell, 1966). Thus, the true K_I value may be only 2.4 times smaller than K_I experimentally observed.

Transition-State Analogs of Chymotrypsin

The results described above would suggest that chymotrypsin-aldehyde complexes might be considered transition state analogs for the enzymatic hydrolysis reaction. It has been forcibly argued that an enzyme will complex most tightly an activated form of its substrate and that such a complex would resemble the transition state for the reaction being catalyzed (Wolfenden, 1972). It is likely, therefore, that a particular substrate analog might also bind very tightly if its structure in the bound complex featured relevant elements of the corresponding substrate in its transition state complex. Because such an analog is predicted to be a powerful inhibitor, the dissociation constant, K_I , may be used to estimate the degree to which this inhibitor-enzyme complex resembles the true transition state. A good transition state analog would be expected to have a K_I significantly lower than that of a comparable Michaelis complex. By this criterion, our aldehyde-chymotrypsin complexes are possible transition state analogs since they have dissociation constants up to 400 times lower than observed K_S values for comparable peptide amide substrates. As previously argued, the hemiacetal (I) is the most reasonable structure for the aldehyde-chymotrypsin complex. Therefore, a plausible candidate for the transition state for chymotrypsin-catalyzed peptide bond hydrolysis might be a

tetrahedral
intermediate

XIII



hemiacetal

I

tetrahedral adduct not very different from the proposed intermediate (XIII).

Recently, alkylboronic acids, which readily form tetrahedral addition complexes, have been proposed as transition state analogs for α -chymotrypsin (Koehler and Lienhard, 1971; Rawn and Lienhard, 1974). Their very low dissociation constants were the first indication that they were bound at the enzyme active site as tetrahedral analogs of the transition state. This proposal has now been supported by X-ray crystallographic (Matthews *et al.*, 1975) and laser Raman spectroscopic studies (Hess and Seybert, 1975).

Effectiveness of Inhibitors with Subtilisin

In addition to chymotrypsin, a number of other well-known proteases possess a reactive serine residue important for catalytic activity. These serine proteases bear a surprising amount of structural and chemical similarities including crystal structure, active site geometry, extended binding site, amino acid sequence, catalytic mechanism, and biological function. Investigations have shown, however, that differences among the serine proteases arise principally from structural variations in substrate specificity. For example, the binding pocket in

subtilisin is more flexible and larger in size than the corresponding binding pocket in chymotrypsin (Kraut, 1971). Consequently, subtilisin manifests a broader substrate and inhibitor specificity at P_1 (e.g. phe, leu, and lys). It seemed reasonable to suppose, therefore, that our aldehydes might be excellent competitive inhibitors of subtilisin. Of the three aldehydes tested (Z-Phe-H, Ac-Ala-Phe-H, and $2-C_{10}H_7CH=CH-CHO$), only Ac-Ala-Phe-H was found to significantly inhibit subtilisin BPN'. With an observed dissociation constant of $1.1 \times 10^{-3} \text{ M}$, this aldehyde binds over 40 times more tightly than a dipeptide amide substrate such as Z-Ala-Leu-NH₂ ($K_S = 4.6 \times 10^{-2} \text{ M}$) (Moriwara *et al.*, 1970). A detailed inhibition study with the other two aldehydes was difficult because of limited solubility. Negligibly small inhibition was observed in both cases.

Ultraviolet Absorption Studies

Having demonstrated that aldehydes were effective inhibitors of chymotrypsin, we rationalized that certain chromophoric analogs would strongly complex with the enzyme and be spectrally sensitive to chemical and physical effects of their environment. Consequently, we designed two reactive and intense ultraviolet-absorbing aldehydes which incorporated the structural features of extended naphthalene π -resonance systems. These aldehydes were expected to complex with chymotrypsin so that the aldehyde functional groups were positioned near Ser-195 and the aromatic nucleus buried in the hydrophobic binding pocket (Figure 5). It was anticipated that the intense $\pi \rightarrow \pi^*$ transitions of these extended resonance systems would occur at longer wavelengths and outside the absorption




Figure 5. Schematic Representation of Possible Binding Interactions Between Two Chromophoric Aldehydes and the Chymotrypsin Active Site.

regions of the constituent tyrosine and tryptophan residues of the enzyme. It was hoped, moreover, that the interaction of these aldehydes with chymotrypsin would result in a derivative that would be sufficiently stable to permit detection of any enzyme-hemiacetal intermediates. As previously described, both aldehydes did favorably inhibit chymotrypsin (Table I) and were observed to display absorption maxima outside the absorption regions of the enzyme. Unfortunately, significant changes in these absorption maxima were not observed when chymotrypsin was reacted with the inhibitors. New absorbances which might have been attributable to hemiacetal formation were not seen either. Small changes accompanying the binding of our aldehydes to the enzyme were difficult to precisely define under the conditions employed in our experiments. Perhaps comparisons between a totally inactive, but not denatured, enzyme might more easily establish the significance of any observed spectral changes. Although the binding of normal phenylalanine derivatives to the active site of chymotrypsin generally cause only small spectral changes to occur (Benmouyal and Trowbridge, 1966; Himoe et al., 1967), our results were disappointing since reports of unusual spectral perturbations have appeared in the literature when aroyl acylating agents were reacted with chymotrypsin ($\Delta\lambda$ as large as 30 nm have been noted) (Charney and Bernhard, 1967).

X-ray Analysis of Inhibited Chymotrypsin A_γ

In both α and γ chymotrypsins, considerable effort has been expended in the search for crystals of enzyme-substrate or enzyme-inhibitor complexes which would be amenable to analysis using difference Fourier techniques. Chloromethyl ketone-A_γ complexes, for example, have

been used in recent studies of the extended binding site of chymotrypsin (Segal, et al., 1971a,b). The advantages of using irreversible inhibitors such as chloromethyl ketones are two-fold: it makes possible the achievement of high occupancy at the binding site in the crystal, and it also permits straightforward characterization of the enzyme. In the present investigation, however, reversible aldehyde inhibitors were chosen for study. Although kinetic experiments showed that our aldehydes were excellent competitive inhibitors of chymotrypsin in solution, analytical methods were not available for testing the effectiveness of our compounds as inhibitors of the enzyme in the crystalline state. Consequently, efforts were directed toward the collection and interpretation of diffraction data from zero-level precession photographs in order to characterize the inhibited enzymes.

In Table II, the cell parameters of inhibited and native chymotrypsin crystals are presented. Inspection of the data will show that inhibition caused no changes in unit cell dimensions greater than 0.5%. Provided that A_Y is truly inhibited, these results suggest that the native and derivative crystals are closely isomorphous. Nevertheless, obvious intensity differences were not noted when native and derivative photographs were visually compared. To circumvent this problem, statistical comparisons of zero-level reflections (measured for Z-Phe-H inhibited and uninhibited A_Y crystals) were attempted. The basis for comparisons were the fractional differences between derivative (I_D) and scaled native (I_N) reflection intensities, $(I_D - RI_N)/I_D$. The scaling factor, $R = \Sigma I_D / \Sigma I_N$, was required because the derivative reflections had been

Table 2. Unit Cell Dimensions of Native and
Inhibited Crystals of Chymotrypsin A_γ
Space Group, P4₂₁2)

Inhibitor	a = b (Å)	c(Å)
None ^a	69.3	97.4
Z-Phe-H	69.0	98.0
Ac-Ala-Phe-H	69.6	96.8

^aNative crystals in 2.4 M phosphate, pH 5.6.

measured using longer exposure times. Fractional differences were calculated for each reflection and quantitatively compared with the standard deviation, σ , calculated for the entire set of 572 reflections. Results indicate that 9 differences were above 3σ , 22 were above 2σ , and 99 were above 1σ ($\sigma = 0.47$). These facts imply that the derivative and native crystals are probably distinct. Alternatively, the slightly misaligned zero-level native photograph may have elevated the calculated standard deviation. Because there were doubts that the direct difference Fourier technique would be effective, further crystallographic studies were not undertaken.

CHAPTER IV

CONCLUSIONS

In conclusion, we have succeeded in synthesizing three peptide aldehydes and related analogs, and have investigated their ability to generate suitable models of the tetrahedral transition state for chymotrypsin-catalyzed substrate hydrolysis. Kinetic studies show that the most effective competitive inhibitor of the group, N-benzyloxy-carbonylphenylalaninal (Z-Phe-H, $K_I = 7.8 \times 10^{-5}$ M), binds to chymotrypsin about 400-fold more tightly than comparable amide substrates. Two other peptide aldehydes, acetylalanylphenylalaninal (Ac-Ala-Phe-H, $K_I = 6.7 \times 10^{-4}$ M) and formylphenylalaninal (CHO-Phe-H, $K_I = 8 \times 10^{-3}$ M) are observed to be less reactive. Only the dipeptide aldehyde, Ac-Ala-Phe-H, is seen to inhibit the homologous serine protease, subtilisin BPN'. In addition to our peptide aldehydes, two intensely chromophoric analogs were also synthesized and are seen to be excellent competitive inhibitors of chymotrypsin. Nevertheless, significant spectral perturbations are not observed when either aldehyde complex is formed. Results of our x-ray crystallographic studies, however, suggest that both Z-Phe-H and Ac-Ala-Phe-H inhibit crystals of chymotrypsin A_Y without causing significant changes in unit cell dimensions. Other kinetic data indicate that semicarbazone derivatives of our peptide aldehydes compete just 7 - 9 times less effectively in chymotrypsin inhibition experiments than the corresponding aldehydes, but that


peptide alcohols are quite unreactive.

It is now generally accepted that the transition state for substrate hydrolysis by serine proteases closely resembles a tetrahedral intermediate in which the catalytic serine hydroxyl group forms a covalent adduct with the carbonyl carbon of the labile bond. On the basis of the kinetic results presented here, together with data from other investigators, we suggest that our aldehydes reversibly bind to chymotrypsin as covalent tetrahedral hemiacetals, and that these enzyme-aldehyde complexes are stereochemically analogous to the tetrahedral transition state for the hydrolysis reaction. Direct evidence for the formation of covalent hemiacetals, however, was not obtained in our experiments.


CHAPTER V

RECOMMENDATIONS

A worthwhile extension of the work reported herein might be a kinetic and crystallographic investigation of the S' binding subsites of chymotrypsin and related proteases using peptide aldehyde imines. S' binding subsites may be defined as those subsites on the enzyme surface which interact with extended peptide substrates on the nitrogen side of the scissionable peptide bond (Figure 6). S binding subsites on the other hand, interact with residues on the carbonyl side of the peptide bond which is cleaved. Imines may be synthesized by coupling a peptide aldehyde with an appropriate amine. Competitive inhibition studies as well as difference Fourier studies could be utilized to elucidate the number and character of the S' binding subsites. Such studies would complement those which have already yielded considerable information on the S binding subsites of serine proteases.



Normal Peptide Substrate



Imine of a Peptide Aldehyde

Note: Amino acid residues, P_1 , P'_1 , and P'_2 , are located at subsites S_1 , S'_1 , and S'_2 , respectively. Normal substrate cleavage occurs between residues P_1 and P'_1 . This scheme was originally proposed by Schechter and Berger (1967).

Figure 6. Scheme for Depicting the Positioning of a Polypeptide Substrate and an Imine of a Peptide Aldehyde in the Binding Site of a Protease.

LITERATURE CITED

- Aoyagi, T., Miyata, S., Nanbo, M., Kojuma, F., Matsuzaki, M., Ishizuka, M., Takeuchi, T., and Umezawa, H. (1969a), J. Antibiot. (Tokyo) 22, 558.
- Aoyagi, T., Takeuchi, A., Matsuzaki, K., Kawamura, K., Kondo, S., Hamadu, M., Maedo, K., and Umezawa, H. (1969b), J. Antibiot (Tokyo), 22, 283.
- Bell, R. P. (1966), Adv. Phys. Arg. Chem. 4, 1.
- Benmouyal, P., and Trowbridge, C. G. (1966), Arch Biochem. Biophys. 115, 67.
- Birktoft, J. J., and Blow, D. M. (1972), J. Mol. Biol. 68, 187.
- Birktoft, J. J., Blow, D. M., Henderson, R., and Steitz, T. A. (1970), Phil. Trans. Roy. Soc. London, Ser. B, 257, 67.
- Birnbaum, S. M., Levintow, L., Kingsley, R. B., and Greenstein, J. P. 1952, J. Mol. Biol. 194, 455.
- Blow, D. M. (1971), Enzymes, 3rd Ed., 3, 185.
- Blow, D. M., Birktoft, J. J., and Hartley, B. S. (1969), Nature (London) 221, 337.
- Brenner, N., Müller, H. R., and Pfister, R. W. (1960), Helv. Chim. Acta 33, 568.
- Charney, E., and Bernhard, S. A. (1967), J. Amer. Chem. Soc. 89, 2726.
- Cunningham, L. (1965), Comprehensive Biochemistry 16, 96.
- Dixon, M. (1953), Biochem. J. 55, 170.
- Dowd, J. E., and Riggs, D. S. (1965), J. Biol. Chem. 240, 863.
- Fersht, A. R., and Requena, Y. (1971), J. Amer. Chem. Soc. 93, 7079.
- Fisher, E. Schoeller, W. (1907), Justus Liebigs Ann. Chem. 357, 1.
- Hartley, B. S. (1964), Nature (London) 201, 1284
- Henderson, A. R. (1971), Anal. Biochem. 42, 143.
- Henderson, R. (1970), J. Mol. Biol. 54, 341.

- Henderson, R., Wright, C. S., Hess, G. P., and Blow, D. M. (1971), Cold Spring Harbor Symp. Quant. Biol. 36, 63
- Hess, G. P. (1971), Enzymes, 3rd Ed. 3, 213.
- Hess, G. P., McCann, J., Ku, E., and McConkey, G. (1970), Phil. Trans. Roy Soc. London (B) 257, 89.
- Hess, G. P., and Seybert, D. (1975), Science 189, 384.
- Himoe, A. Brandt, K. G., and Hess, G. P. (1967), J. Biol. Chem. 242, 3963.
- Israelashvili, S., Gottlieb, Y., Imber, M., and Habas, A. (1951), J. Org. Chem. 16, 1519.
- Ito, A., Tokawa, K., and Shimizu, B. (1972), Biochem. Biophys. Res. Commun. 49, 343.
- Jencks, W. P. (1969), Catalysis in Chemistry and Enzymology, p. 225, New York, N. Y., McGraw-Hill.
- Jutz, C. (1958), Chem. Ber. 91, 1867.
- Kawamura, K., Kondo, S., Maedo, K., and Umezawa, H. (1969), Chem. Pharm. Bull (Tokyo) 17, 1902.
- Koehler, K., and Lienhard, G. E. (1971), Biochemistry, 10, 2477.
- Kondo, S., Kawamura, K., Iwamaga, J., Hamada, M., Aoyagi, T., Maeda, K., Takeuchi, (1969), Chem. Pharm. Bull. (Tokyo) 17, 1896.
- Kraut, J. (1971), Enzymes, 3rd Ed. 3, 547.
- Liljas, A. and Rossmann, M. G. (1974), Ann. Rev. Biochem. 43, 499.
- Maeda, K., Kawamura, K., Konda, S., Aoyagi, T., Takeuchi, T., and Umezawa, H. (1971), J. Antibiot. (Tokyo) 24, 402.
- Matthews, D. A., Alden, R. A., Freer, S. T., Birktoft, J. J., and Kraut, J. (1975), J. Biol. Chem. in press.
- Meedom, B. (1959), Biochem. Biophys. Acta 31, 260.
- Meloun, B., Kluh, I., Kostka, U., Moravek, L., Prusik, Z., Vanecek, B., Keil, B., and Sorm, T. (1966), Biochim. Biophys. Acta 130, 543.
- Moriyama, K., Oka, T., and Tsuzuki, H. (1970), Arch. Biochem. Biophys. 138, 515.
- Neurath, H., and Schwert, G. (1950), Chem. Rev. 46, 69.
- Northrop, J. H., Kunitz, M., and Herriott, R. M. (1948), Crystalline Enzymes, 2nd Ed., New York, N.Y., Columbia Univ. Press.
- Penke, B., Czombos, J., Balaspiri, L., Petres, J., and Kovais, K. (1970), Helv. Chim. Acta 53, 1057.

- Powers, J. C., Baker, B. L., Brown, J., and Chelm, B. K. (1974), J. Amer. Chem. Soc. 96, 238.
- Rawn, J. D., and Lienhard, G. E. (1974). Biochemistry 13, 3124.
- Robillard, G., and Shulman, R. (1974a), J. Mol Biol. 86, 519.
- Robillard, G., and Shulman, R. (1974b), J. Mol. Biol. 86, 541.
- Robillard, G., and Shulman, R. (1972), J. Mol. Biol. 71, 507.
- Rover, M., Poilroux, M., Yashida, A., and Desnuelle, P. (1957), Biochim Biophys. Acta 23, 608.
- Rühlmann, A., Kukla, D., Schwager, P., Bartels, K., and Huber, R. (1973), J. Mol. Biol. 77, 417.
- Saeki, H., Shimada, Y., Kawakita, N., Shimizu, B., Ohki, E., Maeda, K., and Umezawa, H. (1973), Chem. Phar. Bull. (Tokyo) 1, 163.
- Segal, D. M., Powers, J. C., Cohen, G. H., Davies, D. R., and Wilcox, P. E. (1971a) Biochemistry 10, 3728.
- Segal, D. M., Cohen, G. H., Davies, D. R., Powers, J. C., and Wilcox, P. E. (1971b), Cold Spring Harbor Symp. Quant. Biol. 36, 85.
- Shaw, E. (1967), Methods Enzymol. 11, 684.
- Shimizu, B., Saito, A., Ito, A., Tokawa, K., Maeda, K., and Umezawa, H. (1972), J. Antibiot. (Tokyo) 25, 515.
- Schultz, R. M., and Cheerva, A. C. (1975), FEBS (Fed. Eur. Biochem. Soc) Lett. 50, 47.
- Staab, H. A., and Braunling, H. (1962), Justus Liebigs Ann. Chem. 654, 119.
- Steitz, T. A. Henderson, R., and Blow, D. M. (1969), J. Mol. Biol. 46, 337.
- Sweet, R. M., Wright, H. T., Janin, J., Chothia, C. H., and Blow, D. M. (1974) Biochemistry 13, 4212.
- Tannhauser, P., Pratt, R. J., and Jensen, E. V. (1956), J. Amer. Chem. Soc. 78, 2658.
- Thompson, R. C. (1973), Biochemistry 12, 47.
- duVigneaud, V., Dorfmann, R., and Loring, H. S. (1932), J. Biol. Chem. 98, 577.
- Weinstein, B., and Pritchard, A. E. (1972), J. Chem. Soc. Perkin I, 1015.

- Westerik, J. O., and Wolfenden, R. (1972), J. Biol. Chem. 247, 8195.
- Weygand, F., Eberhardt, G., Linden, H., Schafer, F., and Eigen, I. (1953), Angew Chem. 65, 525.
- Wilcox, P. E. (1970), Methods Enzymol 19, 64.
- Wolfenden, R. (1972), Acc. Chem. Res. 5, 10.
- Zeffren, E., and Hall, P. L. (1973), The Study of Enzyme Mechanisms, Chap. 9, 189 ff, New York, N. Y., Wiley and Sons.

PART II

INHIBITION OF ELASTASE BY
TETRAPEPTIDE CHLOROMETHYL KETONES

CHAPTER I

INTRODUCTION

Pulmonary emphysema is believed to result from the uninhibited proteolysis of elastic lung tissue by elastase and related neutral proteases derived from leukocytes and macrophages (Mittman, 1972). Normally, the lungs are protected from proteolytic digestion during infection or inflammation by the protease inhibitor α_1 -antitrypsin. Individuals with a deficiency of α_1 -antitrypsin, however, are biased toward chronic pulmonary lung diseases. The development of appropriate synthetic inhibitors, sufficiently reactive and specific, and capable of replacing α_1 -antitrypsin, might therefore prove to be valuable reagents for the treatment of emphysema, arteritis, arthritis and related diseases. In addition, these elastase inhibitors would be important and relevant reagents for the study of the biological function of elastolytic enzymes. This thesis, Part II, reports the synthesis and reactivity of several tetrapeptide chloromethyl ketones which are both reactive and selective elastase inhibitors.

Background

Elastase, like chymotrypsin and trypsin, is a serine protease, and most characterization studies have been carried out on the readily available porcine pancreatic enzyme (EC. 3.4.21.11). Its inactive precursor, proelastase, is secreted by the pancreas and converted to

active enzyme just before use by another enzyme, trypsin. Elastase has a molecular weight of approximately 25,900, consists of a single polypeptide chain 240 amino acids in length, and contains 4 disulfide bonds (Hartley and Shotton, 1971). The active-site residues essential for catalytic activity have been identified to be Ser-188 and His-45. Optimal activity occurs at pH 8.5. The detailed molecular structures of tosyl elastase and native elastase have been determined from 3.5 Å electron density maps and correlate well with solution kinetic properties (Shotton and Watson, 1970; Shotton, *et al.*, 1971). A charge-relay mechanism of elastase catalysis has been proposed, identical with that for chymotrypsin (Hess, 1971; Hartley and Shotton, 1971). Elastase differs from other serine proteases chiefly in substrate specificity: substrates with uncharged nonaromatic side chains, *e.g.* alanine and valine, are preferred because the entrance to the specificity pocket is blocked by residues Val-216 and Thr-226. Both are glycyl residues in chymotrypsin. Like the other serine proteases, however, elastase is an endopeptidase and shows esterase activity toward synthetic substrates such as Ac-Ala-Ala-Ala-OCH₃. Unlike them, the reactivity of elastase is very dependent on the peptide length of substrates or inhibitors.

A number of proteolytic enzymes are known to occur in human polymorphonuclear (PMN) leukocyte granule fractions, including an elastase which is active at physiological pH(7-8). This human leukocyte elastase has recently been purified by affinity chromatography and partially characterized (Janoff and Scherer, 1968; Janoff, 1973; Folds *et al.*, 1972; Ohlsson and Olsson, 1973). It is known to degrade human

lung elastin, arterial walls and basement membrane, digest proteins of bacteria cell walls in vitro, induce cellular surface changes associated with loss of growth control, and undergo inhibition by α_1 -antitrypsin and peptide chloromethyl ketones (Janoff et al., 1972; Janoff and Blondin, 1973, 1974; Mosser et al., 1973; Janoff, 1972b). Experimental evidence has suggested, furthermore, that human leukocyte elastase may be involved in pathological processes associated with elastic tissue damage in acute arthritis, pulmonary emphysema, and with the tumor-producing action of co-carcinogenic substances (Janoff, 1972a,b; Galdston et al., 1973; Mittman, 1972). Like the more widely studied porcine pancreatic elastase, human leukocyte elastase is a serine protease and exhibits esterase activity toward synthetic substrates such as Boc-Ala-ONp and Ac-Ala-Ala-Ala-OCH₃.

Although a variety of synthetic inhibitors are known to react with elastase, certain peptide chloromethyl ketones have received much recent attention (Powers and Tuhy, 1972, 1973; Tuhy and Powers, 1975; Thompson and Blout, 1973a; Thomson and Deniss, 1973). Chloromethyl ketones form a broad class of inhibitors and have been immensely useful for studying proteolytic enzymes (Shaw, 1970). If properly designed to resemble natural substrates, chloromethyl ketones can be made fairly specific for one serine protease or a group of serine proteases with similar specificity. The reason for the specificity of chloromethyl ketones is apparent upon consideration of the mechanism of action of serine proteases.

As revealed by X-ray crystallographic investigations, the catalytic centers of the serine proteases chymotrypsin, subtilisin, trypsin

and elastase are essentially identical in composition and conformation, all containing a charge-relay system composed of an activated serine, a histidine, and an aspartic acid residue (Hess, 1971; Blow *et al.*, 1969). Furthermore, each enzyme contains a binding pocket adjacent to the catalytic residues whose size and chemistry determine the primary substrate specificity. When a substrate properly binds to the enzyme, the carbonyl group of the scissile peptide bond is oriented in such a way that attack by the active-site serine residue can occur, thus leading to the formation of an acyl enzyme intermediate which rapidly turns over (Figure 1). A similarly bound chloromethyl ketone, however, would place the chloroketone moiety adjacent to the imidazole ring of the active-site histidine residue. Irreversible alkylation *via* formation of a covalent bond between histidine and inhibitor would then occur. The binding modes of peptide chloromethyl ketones with chymotrypsin A_Y (Segal *et al.*, 1971a, b) and subtilisin-BPN' (Robertus *et al.*, 1972; Kraut *et al.*, 1971, 1975; Poulas *et al.*, 1975) have recently been investigated by X-ray crystallography. These enzyme-inhibitor interactions are illustrated in Figures 2 and 3. The phenyl group of chloromethyl ketones was found to be located in the hydrophobic binding pocket, and the peptide chain of an extended inhibitor and a section of the backbone of the enzyme formed a β -sheet structure. The solution inhibition kinetics of these two proteolytic enzymes have also been studied (Kurachi *et al.*, 1973; J. C. Powers and J. T. Tippet, unpublished observations). In general, the greater the enzyme-inhibitor interaction, at the primary as well as the extended binding site, the better the inhibition.






Figure 1. A Schematic Representation of Pancreatic Elastase Reactions with Substrates and Peptide Chloromethyl Ketone Inhibitors.



Note: Only pertinent portions of the protease molecule are shown. This drawing was deduced from X-ray crystallographic studies (Segal *et al.*, 1971).

Figure 2. Illustration Showing the Proposed Binding of Ac-Ala-Phe-CH₂Cl to Chymotrypsin A_γ.



Note: Chymotrypsin (below) and the inhibitor Z-Ala-Leu-Phe-CH₂Cl (above) form an anti-parallel β -pleated sheet structure involving three hydrogen bonds.

Figure 3. Diagram of Chymotrypsin A Showing the Extended Binding Site Region.

Recently, a series of P_1 -alanine peptide chloromethyl ketones have been demonstrated to be fairly reactive and specific inhibitors for porcine pancreatic elastase and human leukocyte elastase (Powers and Tuhy, 1972, 1973; Tuhy and Powers, 1975). These studies defined two important structural features as being necessary for developing an optimally reactive and selective elastase inhibitor. First, the compounds should contain a terminal alanine chloromethyl ketone moiety because elastase has demonstrated a primary specificity for alanine residues (Narayanan and Anwar, 1969; Atlas *et al.*, 1970; Geneste and Bender, 1969; Kaplan *et al.*, 1970; Atlas and Berger, 1972). Second, the inhibitors should contain an extended peptide chain since the rate of substrate hydrolysis is known to be strongly dependent on chain length (Atlas *et al.*, 1970; Atlas and Berger, 1972; Thompson and Blout, 1970, 1973b). This very important feature was shown to enhance inhibitor reactivity, presumably through an increased interaction with the extended binding site of elastase.

Rationale for Development of Elastase Inhibitors

A recent computer study has examined the bonds split by porcine pancreatic elastase in a sampling of polypeptide substrates (Whitley, *et al.*, 1975). Significant correlations were made concerning the amino acids adjacent to the cleaved peptide bonds. Elastase had been thought to exhibit distinctive substrate or inhibitor specificity for alanine residues at P_1 subsites. Surprisingly, the probabilities of peptide bond cleavages after valine (42.9%) and isoleucine (41.7%) residues

were higher than that for alanine (37.1%). In addition, a 29.2% cleavage probability was noted for P_1 -threonine residues. These results suggested that chloromethyl ketones which incorporated the structural features of an extended peptide chain and an isoleucine, valine or threonine at the P_1 position should be synthesized and compared with the known tetrapeptide elastase inhibitor, Ac-Ala-Ala-Pro-Ala-CH₂Cl.

CHAPTER II

EXPERIMENTAL

Materials and Methods

Porcine pancreatic elastase (lot 55B405) was obtained from Whatman Biochemicals Ltd. and used without further purification; its substrate, Boc-Ala-ON_p, was purchased from Sigma Chemical Co. Human leukocyte elastase was gratuitously provided by Dr. Aaron Janoff at S.U.N.Y. at Stony Brook; it was 95% pure as determined by a gel densitometry scan. Chymotrypsin A_α (lot CDIOBK) was obtained from Worthington Biochemical Co., and its substrate, Ac-Tyr-OEt, was synthesized in our laboratory and had mp 80-81°. Trypsin (lot 102C-1920) and its substrate, Bz-Arg-OEt, were obtained from Sigma Chemical Co. The tripeptide ester, Ac-Ala-Ala-Pro-OBz, and the tetrapeptide chloromethyl ketone, Ac-Ala-Ala-Pro-Ala-CH₂Cl, were synthesized by Dr. R. Boone. N-t-Butyloxycarbonyl-L-valine (Boc-Val-OH) was prepared from valine and t-Butylazidoformate using the pH-stat method (Schnabel, 1967), mp 73-75° (lit: 72). Boc-L-isoleucine · 1/2 H₂O and Boc-L-threonine were purchased from Bachem, Inc. and dried under vacuum overnight. All other reagents and solvents were analytical grade. Thin-layer chromatography was performed using Merck silica gel G plates. Elastase inhibition kinetics were performed on a Beckman Model 25 spectrophotometer. Chymotrypsin and trypsin inhibition kinetics were performed on a Radiometer automated pH-stat (model TTTII). Mass spectra were taken on a Hitachi Perkin-

Elmer RMU-7C instrument using a 70 electron volt source, and nuclear magnetic resonance (nmr) spectra were taken on a Varian T-60 instrument. The peak positions in the nmr spectra are reported in ppm relative to tetramethylsilane. The following abbreviations are used: s, singlet; d, doublet; t, triplet; m, multiplet; b, broad.

L-Valine Chloromethyl Ketone Hydrochloride ($\text{HCl} \cdot \text{Val-CH}_2\text{Cl}$)

The diazo ketone Boc-Val-CHN_2 was prepared from Boc-Val-OH (10.0 gm, 45 mmol) and diazomethane using a mixed anhydride method (Penke *et al.*, 1970). Anhydrous HCl was bubbled through a solution of Boc-Val-CHN_2 in ether/tetrahydrofuran at 5°C for 15 minutes as the solution turned from yellow to colorless. The product was isolated, recrystallized from $\text{THF/Et}_2\text{O}$ and dried in vacuo to give 4.5 gram (55%) of an extremely hygroscopic white solid.

N-Acetyl-L-Alanyl-L-Prolyl-L-Valine Chloromethyl Ketone

$\text{Ac-Ala-Ala-Pro-Val-CH}_2\text{Cl}$ was prepared from deblocked $\text{Ac-Ala-Ala-Pro-OBz}$ and $\text{HCl} \cdot \text{Val-CH}_2\text{Cl}$ using a mixed anhydride coupling method (Anderson *et al.*, 1967). Ac-Ala-Ala-Pro-OH (1.5 g, 5 mmol) was dissolved in 50 ml anhydrous tetrahydrofuran and stirred at -15°C while N-methylmorpholine (.55 ml, 5 mmol) and isobutyl chloroformate (.65 ml, 5 mmol) were added. After 10 minutes, the N-methylmorpholine salts were filtered and $\text{HCl} \cdot \text{Val-CH}_2\text{Cl}$ (.93 g, 5 mmol in 5 ml DMF) and N-methylmorpholine (.55 ml, 5 mmol) were added. Stirring was continued for 4 hours as the mixture warmed to 25°C . Then the solvent was removed in vacuo and the resulting yellow oil was dissolved in methanol and chromatographed on Merck silica gel G 0.063-0.2 mm. The product was

isolated after elution with 8% methanol in chloroform. Recrystallization from methanol gave 1.05 g (49%) of a white solid, mp 195-196° (d), R_f 0.41 (CHCl_3 - CH_3OH , 9:1). The nmr spectrum (CDCl_3) showed peaks at 8.23 (1H, d, NH), 7.70 (1H, d, NH), 6.43 (1H, d, NH), 4.77 (4H, m, NHCH(R)CO), 4.23 (2H, s, COCH_2Cl), 3.70 (2H, b, $\text{N-CH}_2\text{-(CH}_2)_2\text{-CH}$), 2.10 (5H, m, $\text{CH(CH}_3)_2$ and $\text{N-CH}_2\text{-(CH}_2)_2\text{CH}$), 2.03 (3H, s, CH_3CO), 1.27 (6H, m, $\text{CH(CH}_3)_2$), and 0.87 (6H, m, $\text{CH(CH}_3)_2\text{CO}$).

The mass spectrum showed major peaks at m/e 430 (M^+), 395 ($M-\text{Cl}$), 353 ($\text{Ac-Ala-Ala-Pro-NHCH(CH(CH}_3)_2)^+$), 282 (Ac-Ala-Ala-Pro^+), 254 ($\text{Ac-Ala-Ala-N-(CH}_2)_3\text{CH}^+$), 238 ($(\text{Ala-Ala-Pro}^+)-\text{H}$), 185 (Ac-Ala-Ala^+), 167 ($(\text{Ala-Pro}^+)-\text{H}$), and 114 (Ac-Ala^+).

Anal. Calcd for $\text{C}_{19}\text{H}_{31}\text{N}_4\text{O}_5\text{Cl}$: C, 52.96; H, 7.20; N, 13.00.

Found: C, 52.67; H, 7.30; N, 12.96

N-Acetyl-L-Alanyl-Alanyl-L-Prolyl-L-Isoleucine Chloromethyl Ketone

$\text{Ac-Ala-Ala-Pro-Ile-CH}_2\text{Cl}$ was prepared similarly to $\text{Ac-Ala-Ala-Pro-Val-CH}_2\text{Cl}$ from $\text{Ac-Ala-Ala-Pro-Ala-OH}$ and $\text{HCl Ile-CH}_2\text{Cl}$ (prepared analogously to $\text{HCl-Val-CH}_2\text{Cl}$). The product was isolated from the residue by chromatography on a silica gel column from which it was eluted with 7% methanol in chloroform. Recrystallization from methanol gave 1.21 g (55%) of a white solid, mp 207-208° (d), R_f 0.49 (CHCl_3 - CH_3OH , 9:1).

The nmr spectrum (CDCl_3) showed peaks at δ 8.27 (1H, d, NH), 7.77 (1H, d, NH), 6.57 (1H, d, NH), 4.77 (4H, m, NHCH(R)CO), 4.27 (2H, s, COCH_2Cl), 3.70 (2H, b, $\text{N-CH}_2\text{-(CH}_2)_2\text{-CH}$), 2.13 (5H, m, $\text{CH(CH(CH}_3)_2\text{CH}_2\text{CH}_3)\text{CO}$ and $\text{N-CH}_2\text{-(CH}_2)_2\text{-CH}$), 1.99 (3H, s, CH_3CO), 1.27 (8H, m, $\text{CH(CH}_3)_2\text{CO}$ and $\text{CH(CH(CH}_3)_2\text{CH}_2\text{CH}_3)\text{CO}$), and 0.90 (6H, m, $\text{CH(CH(CH}_3)_2\text{CH}_2\text{CH}_3)\text{CO}$).

The mass spectrum showed major peaks at m/e 444 (M^+), 367($\text{Ac-Ala-Ala-Pro-NH}(\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3)^+$), 282(Ac-Ala-Ala-Pro^+), 254($\text{Ac-Ala-Ala-N}(\text{CH}_2)_3\text{CH}^+$), 185(Ac-Ala-Ala^+), 167($(\text{Ala-Pro}^+)-\text{H}$), and 114(Ac-Ala^+).

Anal. Calcd for $\text{C}_{20}\text{H}_{33}\text{N}_4\text{O}_5\text{Cl}$: C, 53.99; H, 7.42; N, 12.60.
Found: C, 53.90; H, 7.54; N, 12.61.

N-Acetyl-L-Alanyl-L-Alanyl-L-Prolyl-L-Threonine Chloromethyl Ketone

$\text{Ac-Ala-Ala-Pro-Thr-CH}_2\text{Cl}$ was synthesized from Ac-Ala-Ala-Pro-OH and $\text{HCl}\cdot\text{Thr-CH}_2\text{Cl}$. L-Threonine chloromethyl ketone hydrochloride was prepared similarly to $\text{HCl}\cdot\text{Val-CH}_2\text{Cl}$; in this case the product was isolated as an oil and immediately dissolved in 5 ml dimethylformamide (DMF) for use in a subsequent coupling reaction. Ac-Ala-Ala-Pro-OH (.75 g, 2.5mmol) was dissolved in 50 ml dry tetrahydrofuran and stirred at -15°C while N-methylmorpholine (.28 ml, 2.5mmol) and isobutyl chloroformate (.33 ml, 2.5mmol) were added. After 10 minutes, the solution was filtered and $\text{HCl}\cdot\text{Thr-CH}_2\text{Cl}$ (.43 g, 2.5mmol) and N-methylmorpholine (.28 ml, 2.5 mmol) were added. After stirring 4 hours at 25°C , the solvent was removed in vacuo and the resulting oil chromatographed on a silica gel column. The product was isolated after elution with 9% methanol in chloroform. Recrystallization from ethyl acetate-methanol (100:1) gave .21 g (19%) of a white solid, mp $200-201^\circ$ (d), R_f 0.28 ($\text{CHCl}_3\text{-CH}_3\text{OH}$, 9:1). The nmr spectrum (CDCl_3) showed peaks at δ 8.07(1H, d, NH), 7.67(1H, d, NH), 6.37(1H, d, NH), 4.70(4H, m, CH(R)CO), 4.30(2H, s, COCH}_2\text{Cl}), 3.70(3H, s, N-CH}_2(\text{CH}_2)_2\text{-CH} and CH(OH)CH}_3), 3.10(1H, d, CH(OH)CH}_3), 2.13(4H, m, N-CH}_2-(\text{CH}_2)_2\text{-CH}), 1.97(3H, s, CH}_3\text{CO}) and 1.20(9H, m, CH(CH}_3)).

The mass spectrum showed major peaks at m/e 414 ($M-H_2O$), 397 ($M-Cl$), 378 ($M-H_2O-Cl$), 311 ($Ac-Ala-Ala-Pro-NHCH_2^+$), 282 ($Ac-Ala-Ala-Pro^+$), 254 ($Ac-Ala-Ala-N-(CH_2)_3CH^+$), 185 ($Ac-Ala-Ala^+$), 168 ($Ala-Pro^+$), and 114 ($Ac-Ala^+$); no M^+ peak was observed.

Anal. Calcd for $C_{18}H_{29}N_4O_6Cl$: C, 49.94; H, 6.71; N, 12.95
Found: C, 49.91; H, 6.76; N, 12.89.

Reaction of Porcine Pancreatic Elastase with Inhibitors

Inhibition of porcine pancreatic elastase with the series of tetrapeptide chloromethyl ketones was carried out under pseudo-first-order conditions in solutions which contained at least a ten-fold excess of inhibitor over enzyme. Residual enzymatic activity was measured periodically using the Boc-Ala-ONp spectrophotometric assay (Visser and Blout, 1972). A stock solution of elastase prepared in 1 mM HCl was stored at 4°C and had a concentration of 9.4 μM or 0.24 mg/ml by uv absorbance. Inhibitor solutions (.10 mM or 10.0 mM) were prepared by dissolving a weighed amount of inhibitor in methanol and diluting with pH 5.0 buffer (.1 M acetate) resulting in a 10% methanol solution.

The inhibition reaction was started by mixing 0.5 ml of the inhibitor solution with 0.5 ml of the enzyme solution at 30.0°C and proceeding through at least two half lives. Initial concentrations (total volume of 1.0 ml) were as follows: inhibitor, 0.05 or 5.0 mM; elastase, 4.8 μM ; methanol, 5% (v/v). The reaction was monitored by removing 6-8 aliquots (100 μl each) from the inhibition solution at periodic time intervals and rapidly mixing with 2.0 ml of a 0.2 mM Boc-Ala-ONp substrate solution in a sample cuvette. The substrate solution was buffered at pH 6.5 (0.5 M phosphate) and contained 2% (v/v) CH_3CN . The release of

p-nitrophenol was followed at 347.5 nm for 1.0-1.5 minutes on the uv spectrophotometer. The active elastase concentration did not decrease more than 2% in 1 hour as indicated by control runs which lacked only inhibitor.

For each inhibition reaction the kinetic parameters k_{obsd} and $k_{2\text{nd}} = k_{\text{obsd}}/[I]$ were calculated from eq. 1

$$v = k_{\text{obsd}}[E] = k_{2\text{nd}}[I][E] \quad (1)$$

using a least squares computer program. Correlation coefficients of better than 0.995 were maintained throughout for the linear plots.

Reaction of Human Leukocyte Elastase with Inhibitors

Inhibition experiments with leukocyte elastase were carried out under conditions which minimized the enzyme consumed yet facilitated kinetic measurements. In all inhibition reactions, the final concentration of inhibitor was at least 5-fold greater than the enzyme concentration. Inhibitor solutions were buffered at pH 6.5 (1 M phosphate) and contained 10% (v/v) methanol. Elastase solutions (ca 0.50 mg/ml) were prepared by dissolving a weighed amount of lyophilized enzyme in .1 M phosphate buffer (pH 6.5). The inhibition reaction was started by mixing 0.025 ml of the inhibitor solution with 0.030 ml of the enzyme at 30°C, and proceeding through at least two half-lives. Initial concentrations (total volume of 0.055 ml) were: elastase, 10 μM ; tetrapeptide inhibitor, 0.05, 0.20, 0.40 or 10.0 mM; NaCl, 0.06 M; methanol, 5% (v/v). Enzyme assays were performed by removing 10 μl aliquots at periodic time intervals and rapidly mixing with 0.25 ml of a 0.2 mM Boc-Ala-ON_p substrate solution in a microcuvette. Kinetic analysis were performed as before.

Reaction of Chymotrypsin and Trypsin with Inhibitors

Inhibition experiments with chymotrypsin and trypsin were carried out under conditions virtually identical with those employed in the inhibition reactions with human leukocyte elastase. All inhibition reactions were carried out at 30.0° and pH 6.5. Stock solutions of enzymes and inhibitors were prepared at appropriate concentrations and used quickly. Enzyme concentrations were determined by ultraviolet absorbance. A typical inhibition reaction was started by mixing 0.25 ml of the inhibitor solution, 0.25 ml of methanol, 0.5 ml of the enzyme solution, and 9 ml of .1 F citrate buffer (pH 6.5) and proceeding for 0-4 hours. Initial concentrations were as follows: enzyme, 10 μM ; inhibitor, 0.5 mM - 10.0 mM; and methanol, 5% (v/v).

At various time intervals, an aliquot (100 μl) was removed from the inhibition mixture and assayed for residual enzyme activity using a Radiometer automated pH-stat to measure the initial hydrolysis rate of substrate at pH 7.8. Chymotrypsin was assayed using .01 F N-acetyl-L-tyrosine ethyl ester (Ac-Tyr-OEt) as the substrate and 0.5420 F NaOH as the titrant. The substrate solution contained 0.1 F CaCl_2 and 5% (v/v) methanol. Initial velocities were obtained from the pH-stat recorder tracings of base consumption with respect to time using the method of Henderson (1971). Kinetic analyses were performed as previously described for elastase. Correlation coefficients of better than 0.991 were obtained throughout.

CHAPTER III


RESULTS AND DISCUSSION

Three peptide chloromethyl ketones were synthesized and tested as inhibitors of porcine pancreatic elastase and human leukocyte elastase. By regularly varying the P_1 residues of the inhibitors, the enzyme's primary specificity was studied in an effort to design an optimum elastase inhibitor having a maximum velocity.

Synthesis of the Inhibitors


A series of three tetrapeptide chloromethyl ketones were prepared using a mixed anhydride method. The final steps used in preparing a typical inhibitor, Ac-Ala-Ala-Pro-Val-CH₂Cl, are shown in Figure 4. The exemplary structure of this inhibitor as well as a description of the notation adopted for describing its alignment in the binding site of elastase are presented in Figure 5.

All of the peptide chloromethyl ketones were relatively easy to prepare and handle. Minor difficulties, however, were encountered with the unstable L-threonine chloromethyl ketone hydrochloride intermediate. This compound could not be crystallized but was immediately used in a subsequent coupling reaction. Although the desired coupling reaction was apparently achieved, the fact that the isolation of the product occurred in only 19% yield is presumably explicable on the basis of complicating side reactions which involve the free hydroxyl group.



Tetrapeptide Chloromethyl Ketone

Figure 4. Final Synthetic Steps Used in the Preparation of Ac-Ala-Ala-Pro-Val-CH₂Cl.




Note: The residues P₁ - P₄ are designated according to the notation of Schechter and Berger (1967).

Figure 5. Structure of the Typical Peptide Chloromethyl Ketone Ac-Ala-Ala-Pro-Val-CH₂Cl.

Tetrapeptide chloromethyl ketones were found to be stable in the solid state but to undergo slow hydrolysis in aqueous solution.

Kinetics of Inhibition

The irreversible reaction of an active-site-directed inhibitor with an enzyme may be represented by eq. 2 and 3



$$K_I = \frac{[E][I]}{[E \cdot I]} \quad (3)$$

where $E \cdot I$ represents a noncovalently bound complex of the enzyme with the inhibitor, $E - I$ is the final product with the inhibitor irreversibly bound to the enzyme via a covalent linkage, K_I is the dissociation constant of the $E \cdot I$ complex, and k_3 is the limiting rate of inactivation. If the inhibitor concentration is sufficiently great, then the decrease in the total enzyme concentration ($E + E \cdot I$) in the inhibition reaction follows pseudo-first-order kinetics at any fixed value of $[I]$. In this case, the observed first-order rate constant can be represented by eq. (4)

$$k_{\text{obsd}} = \frac{k_3[I]}{K_I + [I]} \quad (4)$$

(Kitz and Wilson, 1962, Kurachi et al., 1973).

If the chosen inhibitor concentration is approximately equal to K_I ($I \cong K_I$), then the ratio $k_{\text{obsd}}/[I]$ will vary over a range of inhibitor concentrations and both K_I and k_3 can be evaluated. If, on the other hand, the value of K_I should be much greater than the chosen inhibitor

concentration ($K_I > I$), then eq. (4) reduces to eq. (5)

$$\frac{k_{\text{obsd}}}{[I]} = \frac{k_3}{K_I} \quad (5)$$

and the inhibition parameter, k_3/K_I , comparable to a second-order rate constant ($K_{2\text{nd}}$), can be determined.

The reactivity of a series of related inhibitors can be compared on the basis of their relative $k_{\text{obsd}}/[I]$ values. The differences in these $k_{\text{obsd}}/[I]$ values will thus reflect both the effect of structural changes upon binding of inhibitor to enzyme as well as the rate of reaction within the E·I complex. $K_{\text{obsd}}/[I]$ values, however, are subject to distortion from nonlinear concentration effects when $[I] \approx K_I$.

Elastase Inhibition Studies

The series of peptide chloromethyl ketones generally acted as highly reactive irreversible inhibitors of porcine pancreatic and human leukocyte elastase. Kinetic results for the porcine pancreatic enzyme are presented in Table 1 and for the human leukocyte enzyme in Table 2. Relative values of $k_{\text{obsd}}/[I]$ were calculated and are the basis for reactivity comparisons. Reaction conditions were selected in order to obtain feasible reaction rates. Both the inhibitor concentration and pH were decreased to practicable levels so that rates could be accurately measured. Although optimal elastase activity occurs at pH 8.5, rapid inhibition occurred even at pH 5.0. Good pseudo-first-order kinetics were observed in all cases. The specific activity of the enzyme, expressed as $\Delta\text{abs.}/\text{min.}/\mu\text{g}$ enzyme, was .032 in the 2.1 ml

Table 1. Inhibition of Porcine Elastase with Tetrapeptide Chloromethyl Ketones.^a

Inhibitor				$[I] \times 10^4, M$	$10^4 k_{\text{obsd}}^b \text{ sec}^{-1}$ (Std. dev.)	Half-life, min	$k_{\text{obsd}}/[I]$ $M^{-1} \text{ sec}^{-1}$ (rel. values)
P_4	P_3	P_2	P_1				
Ac-Ala-Ala-Pro-Ile-CH ₂ Cl				0.5	24 (.96)	4.8	48 (1.2)
Ac-Ala-Ala-Pro-Val-CH ₂ Cl				0.5	18 (.38)	6.7	35 (0.9)
Ac-Ala-Ala-Pro-Ala-CH ₂ Cl				0.5	20 (.77)	5.8	40 (1.0)
Ac-Ala-Ala-Pro-Thr-CH ₂ Cl				50.0	4.1 (.11)	27.9	.08 (.002)

^aElastase concentration 5 μM , at pH 5.0, 30°C, 5% (v/v) methanol.

^bAverage of three runs.

Table 2. Inhibition of Human Leukocyte Elastase with Tetrapeptide Chloromethyl Ketones.^a

Inhibitor				[I] x 10 ⁴ , M	10 ³ k _{obsd} , sec ⁻¹ (std. dev.)	Half-life, min	k _{obsd} /[I] M ⁻¹ sec ⁻¹ (rel. values)
P ₄	P ₃	P ₂	P ₁				
Ac-Ala-Ala-Pro-Val-CH ₂ Cl				0.5	7.64 (.04) ^b	1.6	160 (49)
Ac-Ala-Ala-Pro-Ile-CH ₂ Cl				0.5	6.38 (.04) ^c	1.9	133 (40)
Ac-Ala-Ala-Pro-Ala-CH ₂ Cl				2.0	.68 (.04)	17.0	3.4
				4.0	1.33 (.03)	8.7	3.3 (1.0)
Ac-Ala-Ala-Pro-Thr-CH ₂ Cl				100.0	1.54 (.03)	8.2	0.15 (.05)

^aElastase concentration 10 μM, at pH 6.5, 30°C, 5% (v/v) methanol.

^bAverage of three runs.

^cAverage of two runs.

porcine pancreatic elastase assay and .020 in the .26 ml human leukocyte elastase assay. Because the peptide chloromethyl ketones hydrolyzed slowly in buffered aqueous solution, the inhibition solutions were always freshly prepared. Just enough methanol (5%, v/v) was added to solubilize the inhibitors at 30°C. In all experiments, the reaction was allowed to proceed through at least two half-lives. No direct evidence was produced to indicate that peptide chloromethyl ketones actually reacted with the active site histidine residue of elastase (His-45). By analogy with related serine proteases, it is almost certain that histidine alkylation does take place. That peptide chloromethyl ketone elastase inhibitors do indeed react with a histidine residue has been verified by Thompson and Blout (1973a).


Effectiveness of Porcine Pancreatic Elastase Inhibitors

The overall rate of an active-site-directed irreversible inhibitor depends both on the amount of E·I complex present at equilibrium as well as the rate-limiting reaction of the bound inhibitor with the enzyme to form the inactivated enzyme (E-I). Covalent bond formation would certainly be influenced by the steric arrangement of the inhibitor with enzyme in the E·I complex and by electronic effects. On the other hand, the dissociation constant, K_I , of the E·I complex is determined primarily by the increase in entropy upon binding the inhibitor to the enzyme. This increase is due presumably to the disruption of water structure. Obviously, a structural change in the inhibitor could affect both the extent of binding to the enzyme, measured by K_I , or the


stereoelectronic relationship between the inhibitor and enzyme in the E·I complex, measured by k_3 . That the affinity of an inhibitor for an enzyme is not necessarily related to the rapidity of inactivation has been shown by Shaw and Glover (1970). Due to the generally low inhibitor concentrations used, these two effects were not separately evaluated in the present study. Instead, a comparison of the effectiveness of the tetrapeptide chloromethyl ketone inhibitors was based on their relative $k_{\text{obsd}}/[I]$ values, thus reflecting both the influence of K_I and k_3 .

An examination of the data in Table 1 will show that both the valine and isoleucine chloromethyl ketones were as effective or slightly more effective than the standard inhibitor, Ac-Ala-Ala-Pro-Ala-CH₂Cl. The best inhibitors of the series, Ac-Ala-Ala-Pro-Ile-CH₂Cl, has a second-order rate constant ($k_{\text{obsd}}/[I]$) equal to $48 \text{ M}^{-1} \text{ sec}^{-1}$ at 30.0°C and pH 5.0. These limited results suggest that the primary specificity pocket of porcine pancreatic elastase is large enough to accommodate Val, Ile and Ala as P₁ inhibitors without fostering steric repulsion and perhaps even provides small hydrophobic interactions.

The peptide chloromethyl ketone, Ac-Ala-Ala-Pro-Thr-CH₂Cl, was discovered to be relatively unreactive toward porcine pancreatic elastase under the inhibition conditions employed here. Enzyme inactivation was observed to be over 400 times slower for this threonine derivative than for the isosteric valine inhibitor.




valine chloromethyl ketone



threonine chloromethyl ketone

This decrease in reactivity was quite surprising and might be interpreted in terms of intermolecular hydrogen-bonding between the hydroxyl group of the threonine chloromethyl ketone and some residue in the catalytic site of elastase. Such an enzyme-inhibitor interaction could force a rotation about the C_α bond of the threonine inhibitor. The result would be a decreased rate of inactivating alkylation within the bound complex due to the altered conformation of the inhibitor. On the other hand, intramolecular inhibitor hydrogen-binding (between the β -OH of threonine and the $\text{C}=\text{O}$ of the adjacent proline) might occur.



Irreversible alkylation via formation of a covalent bond between His-45 and this chloromethylketone would be severely diminished. It is unlikely, however, that the failure of the threonine chloromethyl ketone to effectively inhibit elastase is a result of steric repulsion in the S_1 subsite of the enzyme. Both valine and isoleucine derivatives also have medium-sized alkyl side chains but are seen to react quite rapidly with elastase.

Effectiveness of Human Leukocyte Elastase Inhibitors

A comparison of the peptide chloromethyl ketone inhibitors, based on their relative $k_{\text{obsd}}/[I]$ values, leads to several interesting relationships between the structure of inhibitors and reactivity toward human leukocyte elastase. Two tetrapeptides, Ac-Ala-Ala-Pro-Val-CH₂Cl and Ac-Ala-Ala-Pro-Ile-CH₂Cl were observed to be 40-50 times more reactive than the standard inhibitor, Ac-Ala-Ala-Pro-Ala-CH₂Cl (Table II). This results suggests that the side chains of valine and isoleucine, extending about 2-4 Å from C_α, are better able to make van der Waals contact within the hydrophobic S₁ binding pocket of human elastase. Alanine, on the other hand, has a side chain too small (1-2 Å from C_α) to interact significantly with the enzyme. That hydrophobic bonding is an important driving force for noncovalent intermolecular interactions in aqueous solution has been discussed by Jencks (1969).

The threonine peptide chloromethyl ketone was again observed to be relatively unreactive. An explanation for this behavior with human leukocyte elastase is similar to that outlined for the porcine pancreatic enzyme. The relative reactivity of various P₁ inhibitors with human elastase can be represented by Val, Ile >> Ala > Thr.

Comparisons of the Two Kinds of Elastase

At this point it is of interest to examine certain inhibition characteristics of human leukocyte elastase as compared to the more thoroughly studied porcine pancreatic elastase. The nature of such differences may provide some insight into their separate biological functions. For example, leukocyte elastase generally reacts slightly less rapidly

with the group of peptide chloromethyl ketones than does pancreatic elastase, as indicated by the somewhat smaller values of $k_{\text{obsd}}/[I]$ for inhibition (Table 5). This behavior is most likely due to the lesser specific activity of the leukocyte enzyme. More significantly, however, the P_1 valine or isoleucine chloromethyl ketones were dramatically more reactive than the standard alanine tetrapeptide in the case of leukocyte elastase. This substantial difference in the rates of inhibition definitely establishes that the human leukocyte enzyme is distinct from the porcine pancreatic enzyme.

Inhibition Studies with Trypsin and Chymotrypsin

To be useful in physiological experiments, our chloromethyl ketones should selectively as well as effectively inactivate elastolytic enzymes in preference to such related serine proteases as chymotrypsin and trypsin. Although these proteolytic enzymes are homologous with elastase, they show structural differences at their primary binding sites to accommodate different kinds of substrate P_1 residues. Each enzyme possesses a pronounced pocket adjacent to the catalytic residues having special dimensions and steric and electrostatic properties. For example, chymotrypsin contains a hydrophobic, slot-shaped pocket and can easily accommodate residues with aromatic side chains, e.g. Phe, Tyr and Trp, as well as other large residues such as leucine. Trypsin's binding pocket, on the hand hand, contains an anionic carboxylate group. Consequently, trypsin is specific for amino acid residues with positively-charged side chains such as lysine or arginine. Because the binding pocket of porcine pancreatic elastase is partially crowded with

the alkyl group of Val-216, this enzyme is specific for residues with relatively small alkyl side chains.

Table 3 presents the kinetic results for the attempted inactivation of trypsin with the four tetrapeptide chloromethyl ketones. These compounds were completely unreactive toward trypsin even after 4 hours under our standard inhibition conditions. Consequently, no kinetic constants could be determined. Control experiments without inhibitor indicated, however, that the enzyme remained almost fully active during this time period.

The results for the inhibition experiments with chymotrypsin are shown in Table 4. $K_{\text{obsd}}/[I]$ values appeared to increase as the P_1 alanine, valine and isoleucine side chain residues were made larger. Not surprisingly, these inhibitors were seen to inactivate chymotrypsin only 1 to 6 times less effectively than Boc-Gly-Leu-Phe-CH₂Cl, a chloromethyl ketone reported to be an excellent inhibitor for α -chymotrypsin (Kurachi *et al.*, 1973). As previously mentioned, chymotrypsin is known to show a specificity for P_1 residues possessing aromatic or large hydrophobic alkyl side chains. Since the reaction conditions employed in these inhibition studies with chymotrypsin were virtually identical with those used for the human leukocyte elastase, a direct comparison of results is possible (refer to Table 5). In general, those tetrapeptide inhibitors with Ile, Val or Ala P_1 residues were observed to inactivate chymotrypsin slower than either the human leukocyte or porcine pancreatic elastase enzymes. For example, Ac-Ala-Ala-Pro-Val-CH₂Cl was found to inhibit chymotrypsin with

Table 3. Inhibition of Trypsin with Tetrapeptide Chloromethyl Ketones.^a

Inhibitor				[I] x 10 ⁴ , M	Time (hr)	Activity ^b (%)
P ₄	P ₃	P ₂	P ₁			
Ac-Ala-Ala-Pro-Ile-CH ₂ Cl				0.5	4	88
Ac-Ala-Ala-Pro-Val-CH ₂ Cl				0.5	4	90
Ac-Ala-Ala-Pro-Ala-CH ₂ Cl				2.0	4	87
Ac-Ala-Ala-Pro-Thr-CH ₂ Cl				100.0	4	89
None ^c					4	89

^aTrypsin concentration 10 μM, at pH 6.5, 30.0°, 5% (v/v) methanol

^bEnzyme activity after t (hr) measured as percent of initial activity at t = 0.

^cControl experiment.

Table 4. Inhibition of α -Chymotrypsin with Tetrapeptide Chloromethyl Ketones.^a

Inhibitor				$[I] \times 10^4, M$	$10^4 k_{\text{obsd}}, \text{sec}^{-1}$ (std. dev.)	Half-life, min	$k_{\text{obsd}}/[I]$ $M^{-1} \text{sec}^{-1}$ (rel. values)
P ₄	P ₃	P ₂	P ₁				
Ac-Ala-Ala-Pro-Ile-CH ₂ Cl				0.5	3.20 (.03)	36.1	6.4 (5.8)
Ac-Ala-Ala-Pro-Val-CH ₂ Cl				0.5	.98 (.03)	117.8	2.0 (1.8)
Ac-Ala-Ala-Pro-Ala-CH ₂ Cl				2.0	2.27 (.06)	52.5	1.1 (1.0)
Ac-Ala-Ala-Pro-Thr-CH ₂ Cl				100.0	5.36 (.12)	21.5	.05 (.05)
Boc-Gly-Leu-Phe-CH ₂ Cl							6.6 ^b (6.0)

^aChymotrypsin concentration 10 μM , at pH 6.5, 30.0°, 5% (v/v) methanol.

^bValue adjusted to pH 6.5 from measurement at pH 5.0 (Kurachi *et al.*, 1973) assuming $k_{\text{obsd}}/[I]$ at pH 5.0 would be ca 20% of $k_{\text{obsd}}/[I]$ at pH 6.5.

Table 5. Inhibition of Chymotrypsin and Elastase with Tetrapeptide Chloromethyl Ketones.^a

Inhibitor				Chymotrypsin		Leukocyte Elastase		Porcine Elastase	
P ₄	P ₃	P ₂	P ₁	k _{obsd} /[I] (M ⁻¹ sec ⁻¹)	k _{obsd} /[I] (rel) ^c	k _{obsd} /[I] (M ⁻¹ sec ⁻¹)	k _{obsd} /[I] (rel) ^c	k _{obsd} /[I] (M ⁻¹ sec ⁻¹)	k _{obsd} /[I] (rel) ^c
Ac-Ala-Ala-Pro-Val-CH ₂ Cl				2.0	1.8	160	150	175	160
Ac-Ala-Ala-Pro-Ile-CH ₂ Cl				6.4	5.8	133	120	240	220
Ac-Ala-Ala-Pro-Ala-CH ₂ Cl				1.1	1.0	3.4	3.1	200	180
Ac-Ala-Ala-Pro-Thr-CH ₂ Cl				.05	.04	.15	.04	.4	.002

^aElastase concentration 5-10 μ M, inhibitor concentration 0.05 - 10.0 mM, 5% (v/v) methanol, at 30.0° and pH 6.5.

^bThese values were calculated for pH 6.5 assuming that k_{obsd}/[I] values measured at pH 5.0 would be ca 20% of k_{obsd}/[I] values at pH 6.5 (Powers and Tuhy, 1973).

^cThese three sets of results are on an identical scale.

$k_{\text{obsd}}/[I] = 2.0 \text{ M}^{-1} \text{ sec}^{-1}$ and half-life = 118 minutes. However, this inhibition rate was only about 1% of that observed with the leukocyte elastase. Even the isoleucine chloromethyl ketone, with its somewhat extended alkyl side chain, inhibited chymotrypsin at a rate less than 5% of that observed with the human leukocyte elastase under identical conditions.

Significance of Results

Peptide chloromethyl ketones have proved useful for studies of human leukocyte elastase and its biological activity. For example, Dr. Aaron Janoff has shown that chloromethyl ketones inhibit the digestion of elastin-rich human lung tissue and rat aortic tissue by a human granulocyte elastase in vitro (Janoff, 1972a). A number of further studies using chloroketone inhibitors are currently in progress.

Our results suggest that peptide chloromethyl ketones, if properly designed, can be made fairly specific for human leukocyte elastase. Such specificity is necessary if chloromethyl ketone inhibitors are to be utilized safely in the treatment of emphysema and related diseases. Side reaction interference with other critical biological functions is often a very real problem when drug-type agents are medically evaluated.

CHAPTER IV

CONCLUSIONS

In conclusion, the kinetic results indicate that P_1 -valine, isoleucine and alanine tetrapeptide chloromethyl ketones are reactive and specific inhibitors for both porcine pancreatic elastase and human leukocyte elastase. The analogous threonine chloromethyl ketone was relatively unreactive, presumably due to hydrogen-bonding induced conformational changes. These tetrapeptide inhibitors were also shown to be fairly specific for elastolytic enzymes in preference to trypsin or chymotrypsin. With porcine pancreatic elastase, both the valine and isoleucine chloromethyl ketone inhibitors were as effective or slightly more effective than our standard alanine inhibitor. With human leukocyte elastase, however, the valine and isoleucine inhibitors were markedly more effective than the alanine inhibitor (the best one being Ac-Ala-Ala-Pro-Val-CH₂Cl). This result implies that these two elastolytic enzymes are different and distinct.

Human leukocyte elastase has recently been implicated in the pathology of emphysema and related inflammatory diseases. Eventually chloromethyl ketone inhibitors may become valuable in the treatment of these important diseases.

CHAPTER V

RECOMMENDATIONS

The anomalous kinetic behavior of Ac-Ala-Ala-Pro-Thr-CH₂Cl with elastase reported herein might form the basis for further chemical inquiry. A profitable extension of our work would be to mask the hydroxyl group of the threonine amino acid residue by O-methylation and investigate the reactivity of this new chloromethyl ketone with elastase. This derivative, approximately isosteric with the very reactive isoleucine inhibitor, should be easily accommodated within the primary binding pocket of elastase. A comparison with the relatively ineffective parent inhibitor, therefore, would be meaningful. A rapid rate of inactivation would affirm previous interpretations of the ineffective kinetic behavior of the parent threonine-P₁ inhibitor. A slow rate of inactivation by the masked chloromethyl ketone, however, would not eliminate the possibility that the oxygen of either threonine inhibitor was hydrogen-bonded to some enzyme hydrogen-donor.

LITERATURE CITED

- Anderson, G. W., Zimmerman, J. E., and Callahan, F. M. (1967), J. Amer. Chem. Soc., 89, 5012.
- Atlas, D., and Berger, A. (1972), Biochemistry 11, 4719.
- Atlas, D., Levit, S. Schechter, I., and Berger, A. (1970), FEBS (Fed. Eur. Biochem. Soc.) Lett. 11, 281.
- Blow, D. M., Birktoft, J. J., and Hartley, B. S. (1969), Nature (London), 221, 337.
- Folds, J. D., Welsh, I. R. H., and Spitznagel, J. K. (1972), Proc. Soc. Exp. Biol. Med., 139, 461.
- Galdston, M., Janoff, A., and Davis, A. L. (1973), Am. Rev. Respir. Dis., 107, 718.
- Geneste, P., and Bender, M. L. (1969), Proc. Nat. Acad. Sci. U. S. 64, 683.
- Hartley, B. S., and Shotton, D. M. (1971), Enzymes, 3rd Ed. 3, 323.
- Henderson, A. R. (1971), Anal. Biochem. 42, 143.
- Hess, G. P. (1971), Enzymes, 3rd Ed., 3, 213.
- Janoff, A. (1973), Lab. Invest. 29, 458.
- Janoff, A. (1972a), Amer. J. Pathol. 68, 579.
- Janoff, A. (1972b), Am. Rev. Respir. Dis. 105, 121.
- Janoff, A., and Blondin, J. (1974), Proc. Soc. Exp. Biol. Med. 145, 1427.
- Janoff, A., and Blondin, J. (1973), Lab. Invest. 29, 454.
- Janoff, A., Sandhaus, R. A., Hospelhorn, V. D., and Rosenberg, R. (1972), Proc. Soc. Exp. Biol. Med. 140, 516.
- Janoff, A., and Scherer, J. (1968), J. Exp. Med. 128, 1137.
- Jencks, W. P. (1969), Catalysis in Chemistry and Enzymology, Chap. 8
New York, N. Y., McGraw-Hill.

- Kaplan, H., Symonds, U. B., Dugas, H., and Whitaker, D. R. (1970), Can. J. Biochem. 48, 649.
- Kitz, R., and Wilson, I. (1962), J. Biol. Chem. 237, 3245.
- Kraut, J., Robertus, J. D., Birktoft, J. J., Alden, R. A., Wilcox, P. E., and Powers, J. C. (1971), Cold Spring Harbor Symp. Quant. Biol. 36, 117.
- Kurachi, K., Powers, J. C., and Wilcox, P. E. (1973), Biochemistry, 12, 771.
- Mittman, C., Ed. (1972), Pulmonary Emphysema and Proteolysis, New York, N. Y., Academic Press.
- Mosser, A. G., Janoff, A., and Blondin, J. (1973), Cancer Res. 33, 1092.
- Narayanan, A. S., and Anwar, R. A. (1969), Biochem. J. 114, 11.
- Ohlsson, K., and Olsson, I. (1973). Eur. J. Biochem. 36, 473.
- Penke, B., Czombos, J., Balaspiri, L., Petres, J., and Kovacs, K. (1970), Helv. Chim. Acta 53, 1057.
- Poulos, T. L., Alden, R. A., Freer, S. T., Birktoft, J. J., and Kraut, J. (1975), J. Biol. Chem. in press.
- Powers, J. C., and Tuhy, P. M. (1973), Biochemistry 12, 4767.
- Powers, J. C., and Tuhy, P. M. (1972), J. Amer. Chem. Soc. 94, 6544.
- Robertus, J. D., Alden, R. A., Birktoft, J. J., Kraut, J., Powers, J. C., and Wilcox, P. E. (1972), Biochemistry 11, 2439.
- Schechter, I., and Berger, A. (1967), Biochem. Biophys. Res. Commun. 27, 157.
- Schnabel, E. (1967), Liebigs Ann. Chem. 702, 188.
- Segal, D. M., Powers, J. C., Cohen, G. H., Davis, O. R., and Wilcox, P. E. (1971a), Biochemistry 10, 3728.
- Segal, D. M., Cohen, G. H., Davies, D. R., Powers, J. C., and Wilcox, P. E. (1971b), Cold Spring Harbor Symp. Quant. Biol. 36, 85.
- Shaw, E., and Glover, G. (1970), Arch. Biochem. Biophys. 139, 298.
- Shotton, D. M., and Watson, H. C. (1970), Nature (London) 225, 811.

- Shotton, D. M., White, N. J., and Watson, H. C. (1971), Cold Spring Harbor Symp. Quant. Biol. 36, 91.
- Thompson, R. C., and Blout, E. R. (1973a), Biochemistry 12, 44.
- Thompson, R. C., and Blout, E. R. (1973b), Biochemistry 12, 57.
- Thompson, R. C., and Blout, E. R. (1970), Proc. Nat. Acad. Sci. U.S. 67, 1734.
- Thomson, A., and Denniss, I. S. (1973), Eur. J. Biochem. 38, 1.
- Tuhy, P. M., and Powers, J. C. (1975), FEBS (Fed. Eur. Biochem. Soc.) Lett. 50, 359.
- Visser, L., and Blout, E. R. (1972), Biochim. Biophys. Acta 268, 257.
- Whitley, R. J., Harley, D., and Powers, J. C. (1975), article in preparation.

VITA

Ronald Jay Whitley, the eldest son of Jay Charles and Mary Ruth Whitley, was born February 21, 1948 in Summerville, Georgia. He attended secondary schools in Chicago, Illinois and Trion, Georgia, and was graduated from Trion High School with highest honor May 30, 1966. That September he entered the Georgia Institute of Technology and was graduated with a Bachelor of Science in Chemistry June 13, 1970. He remained at Georgia Tech to earn a Ph.D. in Chemistry. His research in bioorganic chemistry was directed by Dr. James C. Powers. During this time, he was supported by National Institutes of Health Research Grants and Graduate Teaching Assistantships. In September, 1975 he accepted an appointment as a Mayo Research Fellow, Mayo Clinic, Rochester, Minnesota. His chief leisure activities are music, especially classical piano, and backpacking.